Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
>,1485369,terminal half-life,"The drug is not cleared rapidly, with a terminal half-life of > 13 hours as calculated by model-independent parameters.",Pharmacokinetics of rapamycin: single-dose studies in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1485369/),h,13,1196,DB00877,Sirolimus
,15049798,Half-life (T(1/2)),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,9.7,1318,DB00877,Sirolimus
,15049798,Half-life (T(1/2)),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,9.6,1319,DB00877,Sirolimus
,15049798,terminal T(1/2),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,10.8,1320,DB00877,Sirolimus
,15049798,terminal T(1/2),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,12.1,1321,DB00877,Sirolimus
,20564143,AUC-based accumulation factors,"Mean+/-standard deviation AUC-based accumulation factors for everolimus on Days 8 and 15 were 1.16+/-0.37 and 1.42+/-0.42, respectively.","Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),,1.16,3930,DB00877,Sirolimus
,20564143,AUC-based accumulation factors,"Mean+/-standard deviation AUC-based accumulation factors for everolimus on Days 8 and 15 were 1.16+/-0.37 and 1.42+/-0.42, respectively.","Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),,1.42,3931,DB00877,Sirolimus
,20564143,Day 1,Docetaxel Day 1 half-life was 9.4+/-3.4 hours.,"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),h,9.4,3932,DB00877,Sirolimus
,20564143,half-life,Docetaxel Day 1 half-life was 9.4+/-3.4 hours.,"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564143/),h,9.4,3933,DB00877,Sirolimus
,15996252,trough level,"TAC was given at 0.14+/-0.09 mg/kg/day, resulting in a trough level of 6.3+/-2.5 ng/mL.",Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15996252/),[ng] / [ml],6.3,5583,DB00877,Sirolimus
,12200787,time to reach the peak concentration,The time to reach the peak concentration was 1 hour in all patients.,"Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200787/),h,1,9132,DB00877,Sirolimus
,23579358,AUC,"A Bayesian dose-escalation model was used to identify feasible daily or weekly everolimus doses given with paclitaxel (200 mg/m(2) q21 days) and carboplatin (AUC 6 mg/mL/min q21 days) (step 1) and paclitaxel (200 mg/m(2) q21 days), carboplatin (AUC 6 mg/mL/min q21 days), and bevacizumab (15 mg/kg q21 days) (step 2).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),[mg] / [min·ml],6,11334,DB00877,Sirolimus
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,16.7,11335,DB00877,Sirolimus
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,30.8,11336,DB00877,Sirolimus
,23579358,DLT rate,"End-of-cycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly).","Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23579358/),%,30.0,11337,DB00877,Sirolimus
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,52,11753,DB00877,Sirolimus
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,35,11754,DB00877,Sirolimus
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,30,11755,DB00877,Sirolimus
,26020699,maximum solubility,A kinetic solubility test demonstrated that the sirolimus/E-SD/TPGS (1/8/1) solid dispersion had a maximum solubility of 196.7 μg/mL within 0.5 h that gradually decreased to 173.4 μg/mL after 12 h.,Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® e. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26020699/),[μg] / [ml],196.7,12101,DB00877,Sirolimus
,26020699,maximum solubility,A kinetic solubility test demonstrated that the sirolimus/E-SD/TPGS (1/8/1) solid dispersion had a maximum solubility of 196.7 μg/mL within 0.5 h that gradually decreased to 173.4 μg/mL after 12 h.,Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® e. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26020699/),[μg] / [ml],173.4,12102,DB00877,Sirolimus
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],6.6,12867,DB00877,Sirolimus
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],26,12868,DB00877,Sirolimus
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,22,12869,DB00877,Sirolimus
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,105,12870,DB00877,Sirolimus
,12235265,T(max),Median T(max) (1.5-2 h) was unchanged.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),h,1.5-2,12871,DB00877,Sirolimus
,12235265,IC(50),"Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC(50) of 0.625 to 1.25 microM (cyclosporine caused >80% inhibition at 5 microM).",Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),μM,0.625 to 1.25,12872,DB00877,Sirolimus
,30129060,steady-state mean,"The steady-state mean areas under the concentration-time curves of lenvatinib and everolimus were 3220 and 401 ng·h/mL, respectively.",Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30129060/),[h·ng] / [ml],3220,13995,DB00877,Sirolimus
,30129060,areas under the concentration-time curves,"The steady-state mean areas under the concentration-time curves of lenvatinib and everolimus were 3220 and 401 ng·h/mL, respectively.",Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30129060/),[h·ng] / [ml],3220,13996,DB00877,Sirolimus
,30129060,areas under the concentration-time curves,"The steady-state mean areas under the concentration-time curves of lenvatinib and everolimus were 3220 and 401 ng·h/mL, respectively.",Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30129060/),[h·ng] / [ml],401,13997,DB00877,Sirolimus
outside,19817503,AUC(12),Fifty-two percent of the observed AUC(12) values (three periods) in the 40 patients receiving a fixed dose of mycophenolate mofetil 750 mg twice daily were outside the recommended therapeutic range (30-60 microg x h/mL).,Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19817503/),[h·μg] / [ml],30-60,15549,DB00877,Sirolimus
,12616666,bioavailability,"The bioavailability of everolimus from the dispersible tablet was 10% lower relative to the conventional tablet, with a ratio (90% confidence interval) of 0.90 (0.76-1.07).","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),%,10,17074,DB00877,Sirolimus
,12616666,AUC ratio,"Overall absorption, however, was not affected by food inasmuch as the fed/fasting AUC ratio was 0.99 (0.83-1.17).","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),,0.99,17075,DB00877,Sirolimus
,12616666,Cmin,"The corresponding steady-state parameters were as follows: Cmin, 4.4 +/- 1.7 ng/ml; Cmax, 13.6 +/- 4.2 ng/ml; and AUC, 87 +/- 27 ng.h/ml.","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),[ng] / [ml],4.4,17076,DB00877,Sirolimus
,12616666,Cmax,"The corresponding steady-state parameters were as follows: Cmin, 4.4 +/- 1.7 ng/ml; Cmax, 13.6 +/- 4.2 ng/ml; and AUC, 87 +/- 27 ng.h/ml.","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),[ng] / [ml],13.6,17077,DB00877,Sirolimus
,12616666,AUC,"The corresponding steady-state parameters were as follows: Cmin, 4.4 +/- 1.7 ng/ml; Cmax, 13.6 +/- 4.2 ng/ml; and AUC, 87 +/- 27 ng.h/ml.","Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616666/),[h·ng] / [ml],87,17078,DB00877,Sirolimus
,11523724,trough concentration,"Target trough concentration ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 microg/L is appropriate if cyclosporin is being used at trough concentrations of 75 to 150 microg/L.",Clinical pharmacokinetics of sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523724/),[μg] / [l],5 to 15,20590,DB00877,Sirolimus
,11523724,trough concentrations,"Target trough concentration ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 microg/L is appropriate if cyclosporin is being used at trough concentrations of 75 to 150 microg/L.",Clinical pharmacokinetics of sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523724/),[μg] / [l],75 to 150,20591,DB00877,Sirolimus
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,48.0,21662,DB00877,Sirolimus
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,21.2,21663,DB00877,Sirolimus
,20442358,neo,"At 28 days, there was less neointimal thickness with Combo (0.173+/-0.088 mm) compared with Cypher (0.358+/-0.225 mm), LD-Combo (0.316+/-0.228 mm), and Xience V (0.305+/-0.252 mm; P<0.00001).",Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20442358/),mm,0.173,24365,DB00877,Sirolimus
,28357727,clearance,Non-compartmental and population pharmacokinetic-based simulations indicated significant increases in everolimus Cmax and AUC0-24 on day 28 and decreased clearance to 13.41 L/hr.,A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28357727/),[l] / [h],13.41,24436,DB00877,Sirolimus
,16563975,C0,This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml).,Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563975/),[ng] / [ml],6.6,24661,DB00877,Sirolimus
,9129559,blood/plasma ratio,"Sirolimus distribution between whole blood and plasma was concentration-independent, with a mean blood/plasma ratio (coefficient of variation) of 30.9 (48.5%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),,30.9,24920,DB00877,Sirolimus
,9129559,terminal half-life,"Elimination was not influenced by dose, as shown by estimates of the terminal half-life of 63 hours (27.5%) and apparent oral blood clearance of 8.9 L/hr (38.2%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),h,63,24921,DB00877,Sirolimus
,9129559,apparent oral blood clearance,"Elimination was not influenced by dose, as shown by estimates of the terminal half-life of 63 hours (27.5%) and apparent oral blood clearance of 8.9 L/hr (38.2%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),[l] / [h],8.9,24922,DB00877,Sirolimus
,9129559,absorption lag-time,"Sirolimus was rapidly absorbed, as shown by the absorption lag-time of 0.27 hour (35.1%), and ka of 2.77 hr-1 (48.4%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),h,0.27,24923,DB00877,Sirolimus
,9129559,ka,"Sirolimus was rapidly absorbed, as shown by the absorption lag-time of 0.27 hour (35.1%), and ka of 2.77 hr-1 (48.4%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),1/[h],2.77,24924,DB00877,Sirolimus
,26274696,time of the conversion,Mean time of the conversion was 61 months after transplantation.,Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),month,61,25023,DB00877,Sirolimus
,26274696,trough blood concentration,"In the first 7 patients, the initial EVR dose of 3 mg BID resulted in mean EVR trough blood concentration of 14.7 ± 3.7 ng/mL at day 7.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],14.7,25024,DB00877,Sirolimus
,26274696,trough blood concentration,"Four weeks after conversion, mean EVR dose was 1.7 ± 0.5 mg BID (7 patients were receiving 1 mg BID and 17 were receiving 2 mg BID) resulting in mean EVR trough blood concentration of 4.0 ± 1.4 ng/mL.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.0,25025,DB00877,Sirolimus
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],13.4,25026,DB00877,Sirolimus
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],22.9,25027,DB00877,Sirolimus
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],232,25028,DB00877,Sirolimus
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],366,25029,DB00877,Sirolimus
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],78.2,25030,DB00877,Sirolimus
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],102.5,25031,DB00877,Sirolimus
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],3.7,25032,DB00877,Sirolimus
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.1,25033,DB00877,Sirolimus
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],87,25579,DB00877,Sirolimus
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],900,25580,DB00877,Sirolimus
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],"164,000",25581,DB00877,Sirolimus
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],"186,000",25582,DB00877,Sirolimus
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],392,25583,DB00877,Sirolimus
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],643,25584,DB00877,Sirolimus
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],870,25585,DB00877,Sirolimus
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],67.1,25586,DB00877,Sirolimus
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],71.6,25587,DB00877,Sirolimus
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],101,25588,DB00877,Sirolimus
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,265,25589,DB00877,Sirolimus
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,394,25590,DB00877,Sirolimus
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,310,25591,DB00877,Sirolimus
,27185573,Time to response,"Time to response was 41 d, and progression occurred at 126 d.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),d,41,25592,DB00877,Sirolimus
,24089446,MTD,"Thus, the MTD was declared at 100 mg/m(2).",Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089446/),mg,100,25922,DB00877,Sirolimus
,28762135,C max,"On the 10 mg once-daily schedule, C max, minimum concentration (C min), and area under the concentration-time curve from time zero to 24 h (AUC24) were 61.5 ng/mL [mean percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL (CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively.",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],61.5,26563,DB00877,Sirolimus
,28762135,minimum concentration (C min),"On the 10 mg once-daily schedule, C max, minimum concentration (C min), and area under the concentration-time curve from time zero to 24 h (AUC24) were 61.5 ng/mL [mean percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL (CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively.",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],9.6,26564,DB00877,Sirolimus
,28762135,area under the concentration-time curve from time zero to 24 h (AUC24),"On the 10 mg once-daily schedule, C max, minimum concentration (C min), and area under the concentration-time curve from time zero to 24 h (AUC24) were 61.5 ng/mL [mean percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL (CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively.",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[h·ng] / [ml],435,26565,DB00877,Sirolimus
,28762135,C max,"Switching to the 5 mg twice-daily schedule resulted in a reduction of C max to 40.3 ng/mL (CV% 46.6) (p = 0.013), while maintaining AUC24 at 436 ng h/mL (CV% 34.8) (p = 0.952).",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],40.3,26566,DB00877,Sirolimus
,28762135,AUC24,"Switching to the 5 mg twice-daily schedule resulted in a reduction of C max to 40.3 ng/mL (CV% 46.6) (p = 0.013), while maintaining AUC24 at 436 ng h/mL (CV% 34.8) (p = 0.952).",Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[h·ng] / [ml],436,26567,DB00877,Sirolimus
,28762135,C min,C min increased to 13.7 ng/mL (CV% 53.9) (p = 0.018).,Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),[ng] / [ml],13.7,26568,DB00877,Sirolimus
,28762135,C max/C min ratio,The C max/C min ratio was reduced from 6.44 (CV% 36.2) to 3.18 (CV% 35.5) (p < 0.001).,Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),,6.44,26569,DB00877,Sirolimus
,28762135,C max/C min ratio,The C max/C min ratio was reduced from 6.44 (CV% 36.2) to 3.18 (CV% 35.5) (p < 0.001).,Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28762135/),,3.18,26570,DB00877,Sirolimus
,23265712,overall survival,Median overall survival was 9.4 months; progression-free survival was 5.5 months.,A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23265712/),month,9.4,28714,DB00877,Sirolimus
,23265712,progression-free survival,Median overall survival was 9.4 months; progression-free survival was 5.5 months.,A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23265712/),month,5.5,28715,DB00877,Sirolimus
,14620947,accumulation ratio,The accumulation ratio of cerivastatin (after 3 months/ Day 1) was 1.6.,"Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620947/),,1.6,28833,DB00877,Sirolimus
,11069439,"area under the blood concentration-time curve to 12 h (AUC(0,12 h))","The mean area under the blood concentration-time curve to 12 h (AUC(0,12 h)) was 4244 +/- 1311 microg l-1 h for cyclosporin before SDZ RAD treatment and 4683 +/- 1174 microg l-1 h (P = 0.106) on the day of SDZ RAD treatment (95% CI for difference -126, 1003).",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],4244,29800,DB00877,Sirolimus
,11069439,"area under the blood concentration-time curve to 12 h (AUC(0,12 h))","The mean area under the blood concentration-time curve to 12 h (AUC(0,12 h)) was 4244 +/- 1311 microg l-1 h for cyclosporin before SDZ RAD treatment and 4683 +/- 1174 microg l-1 h (P = 0.106) on the day of SDZ RAD treatment (95% CI for difference -126, 1003).",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],4683,29801,DB00877,Sirolimus
,11069439,"AUC(0,24 h)","The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],35.4,29802,DB00877,Sirolimus
,11069439,Cmax,"The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[μg] / [l],7.9,29803,DB00877,Sirolimus
,11069439,tmax,"The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),h,1.5,29804,DB00877,Sirolimus
<,10770413,trough,There was a significant association between trough values expressed as either observed ( < 5 ng/mL) or dose-corrected parameter ( < 1.7 ng/mL per mg administered drug) and the occurrence and severity of acute rejection episodes - despite the low overall incidence of 23 episodes among the cohort of 150 patients.,Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770413/),[ng] / [ml],5,30133,DB00877,Sirolimus
<,10770413,trough,There was a significant association between trough values expressed as either observed ( < 5 ng/mL) or dose-corrected parameter ( < 1.7 ng/mL per mg administered drug) and the occurrence and severity of acute rejection episodes - despite the low overall incidence of 23 episodes among the cohort of 150 patients.,Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770413/),[ng] / [ml],1.7,30134,DB00877,Sirolimus
above,10770413,trough concentrations,"Similarly, ROC functions showed a correlation of the occurrence of hypertriglyceridemia, thrombocytopenia, and leukopenia, but not hypercholesterolemia, with trough concentrations above 15 ng/mL.",Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770413/),[ng] / [ml],15,30135,DB00877,Sirolimus
,10823378,t(max),"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),h,1 to 2,30721,DB00877,Sirolimus
,10823378,systemic availability (F,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),%,14,30722,DB00877,Sirolimus
,10823378,partitioning into,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,36,30723,DB00877,Sirolimus
,10823378,B/P,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,36,30724,DB00877,Sirolimus
,10823378,apparent volume of distribution,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),[l] / [kg],1.7,30725,DB00877,Sirolimus
,10823378,terminal half-life,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),h,62,30726,DB00877,Sirolimus
,10823378,therapeutic window,A whole-blood sirolimus therapeutic window of 5 to 15 ng/mL (measured by microparticle enzyme immunoassay) is recommended for patients at standard risk of rejection.,Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,5 to 15,30727,DB00877,Sirolimus
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,17,31814,DB00877,Sirolimus
,32436621,metabolic response rate,The metabolic response rate in FDG-PET was 17% on day 5 and 20% on day 14.,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),%,20,31815,DB00877,Sirolimus
,32436621,progression free survival (PFS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,3.25,31816,DB00877,Sirolimus
,32436621,overall survival (OS),"Median progression free survival (PFS) and overall survival (OS) were 3.25 and 5.85 months, respectively.",Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32436621/),month,5.85,31817,DB00877,Sirolimus
,30627287,time to reach peak concentration,Non-compartmental analysis demonstrated time to reach peak concentration of sirolimus between 0.5 h to 3 h after scaffold implantation.,Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627287/),h,0.5,32424,DB00877,Sirolimus
,30627287,time to reach peak concentration,Non-compartmental analysis demonstrated time to reach peak concentration of sirolimus between 0.5 h to 3 h after scaffold implantation.,Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627287/),h,3,32425,DB00877,Sirolimus
,30627287,peak concentration (Cmax),"The peak concentration (Cmax) was deduced to be 7.47 ± 2.61 ng/mL, AUC was 436.45 ± 171.24 h·ng/mL, and the t½ was observed at 98.59 ± 33.58 h.",Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627287/),[ng] / [ml],7.47,32426,DB00877,Sirolimus
,30627287,AUC,"The peak concentration (Cmax) was deduced to be 7.47 ± 2.61 ng/mL, AUC was 436.45 ± 171.24 h·ng/mL, and the t½ was observed at 98.59 ± 33.58 h.",Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627287/),[h·ng] / [ml],436.45,32427,DB00877,Sirolimus
,30627287,t½,"The peak concentration (Cmax) was deduced to be 7.47 ± 2.61 ng/mL, AUC was 436.45 ± 171.24 h·ng/mL, and the t½ was observed at 98.59 ± 33.58 h.",Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627287/),h,98.59,32428,DB00877,Sirolimus
,30627287,clearance,The clearance was 0.66 ± 0.16 L/h and lower limit of quantification was detectable at 14.1 days.,Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30627287/),[l] / [h],0.66,32429,DB00877,Sirolimus
,26709938,terminal half-life,"Mean ± SD blood rapamycin terminal half-life, area under the concentration-time curve from 0 to 48 hours after dosing, and maximum concentration were 38.7 ± 12.7 h, 140 ± 23.9 ng•h/mL, and 8.39 ± 1.73 ng/mL, respectively, for experiment 1, and 99.5 ± 89.5 h, 126 ± 27.1 ng•h/mL, and 5.49 ± 1.99 ng/mL, respectively, for experiment 2.",Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709938/),h,38.7,33597,DB00877,Sirolimus
,26709938,area under the concentration-time curve from 0 to 48 hours,"Mean ± SD blood rapamycin terminal half-life, area under the concentration-time curve from 0 to 48 hours after dosing, and maximum concentration were 38.7 ± 12.7 h, 140 ± 23.9 ng•h/mL, and 8.39 ± 1.73 ng/mL, respectively, for experiment 1, and 99.5 ± 89.5 h, 126 ± 27.1 ng•h/mL, and 5.49 ± 1.99 ng/mL, respectively, for experiment 2.",Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709938/),[h·ng] / [ml],140,33598,DB00877,Sirolimus
,26709938,area under the concentration-time curve from 0 to 48 hours,"Mean ± SD blood rapamycin terminal half-life, area under the concentration-time curve from 0 to 48 hours after dosing, and maximum concentration were 38.7 ± 12.7 h, 140 ± 23.9 ng•h/mL, and 8.39 ± 1.73 ng/mL, respectively, for experiment 1, and 99.5 ± 89.5 h, 126 ± 27.1 ng•h/mL, and 5.49 ± 1.99 ng/mL, respectively, for experiment 2.",Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709938/),h,99.5,33599,DB00877,Sirolimus
,26709938,area under the concentration-time curve from 0 to 48 hours,"Mean ± SD blood rapamycin terminal half-life, area under the concentration-time curve from 0 to 48 hours after dosing, and maximum concentration were 38.7 ± 12.7 h, 140 ± 23.9 ng•h/mL, and 8.39 ± 1.73 ng/mL, respectively, for experiment 1, and 99.5 ± 89.5 h, 126 ± 27.1 ng•h/mL, and 5.49 ± 1.99 ng/mL, respectively, for experiment 2.",Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709938/),[h·ng] / [ml],126,33600,DB00877,Sirolimus
,26709938,maximum concentration,"Mean ± SD blood rapamycin terminal half-life, area under the concentration-time curve from 0 to 48 hours after dosing, and maximum concentration were 38.7 ± 12.7 h, 140 ± 23.9 ng•h/mL, and 8.39 ± 1.73 ng/mL, respectively, for experiment 1, and 99.5 ± 89.5 h, 126 ± 27.1 ng•h/mL, and 5.49 ± 1.99 ng/mL, respectively, for experiment 2.",Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709938/),[ng] / [ml],8.39,33601,DB00877,Sirolimus
,26709938,maximum concentration,"Mean ± SD blood rapamycin terminal half-life, area under the concentration-time curve from 0 to 48 hours after dosing, and maximum concentration were 38.7 ± 12.7 h, 140 ± 23.9 ng•h/mL, and 8.39 ± 1.73 ng/mL, respectively, for experiment 1, and 99.5 ± 89.5 h, 126 ± 27.1 ng•h/mL, and 5.49 ± 1.99 ng/mL, respectively, for experiment 2.",Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26709938/),[ng] / [ml],5.49,33602,DB00877,Sirolimus
,34041638,Ctrough,The optimal Ctrough cutoff predicting DLT development was 17.3 ng/mL.,Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,33999,DB00877,Sirolimus
≥,34041638,Ctrough,"The cumulative incidence of DLTs was significantly higher in patients with Ctrough ≥17.3 ng/mL than in other patients (sub-hazard ratio 4.87, 95 % confidence interval [CI] 1.53-15.5; P = 0.007).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,34000,DB00877,Sirolimus
,34041638,PFS,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,327,34001,DB00877,Sirolimus
,34041638,PFS,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,194,34002,DB00877,Sirolimus
,34041638,steady-state Ctrough,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,327,34003,DB00877,Sirolimus
,34041638,steady-state Ctrough,"Furthermore, the median PFS was numerically longer in patients who maintained a steady-state Ctrough below the threshold than in those who did not (327 days [95 % CI 103-355 days] vs. 194 days [95 % CI 45 days-not estimable]; P = 0.35).",Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),d,194,34004,DB00877,Sirolimus
,34041638,Ctrough,The suggested upper threshold for the therapeutic window of everolimus Ctrough was 17.3 ng/mL.,Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34041638/),[ng] / [ml],17.3,34005,DB00877,Sirolimus
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,32,36262,DB00877,Sirolimus
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,24,36263,DB00877,Sirolimus
,18202410,maximum-tolerated dose (MTD),The maximum-tolerated dose (MTD) was 18.75 mg/d.,Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18202410/),[mg] / [d],18.75,38586,DB00877,Sirolimus
,18202410,MTD,The MTD of this phase I trial using an accelerated titration design was determined to be 18.75 mg/d.,Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18202410/),[mg] / [d],18.75,38587,DB00877,Sirolimus
,12752317,Cmins,"Cmins averaged 4.3 +/- 2.4 and 7.2 +/- 4.2 ng/mL at 0.75 and 1.5 mg bid, indicating a 20% under-proportionality at the upper dose level.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[ng] / [ml],4.3,40943,DB00877,Sirolimus
,12752317,Cmins,"Cmins averaged 4.3 +/- 2.4 and 7.2 +/- 4.2 ng/mL at 0.75 and 1.5 mg bid, indicating a 20% under-proportionality at the upper dose level.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[ng] / [ml],7.2,40944,DB00877,Sirolimus
,12752317,AUC,"AUC was dose-proportional and stable over time, averaging 77 +/- 32 and 136 +/- 57 ng.h.mL-1 at the two dose levels.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[h·ng] / [ml],77,40945,DB00877,Sirolimus
,12752317,AUC,"AUC was dose-proportional and stable over time, averaging 77 +/- 32 and 136 +/- 57 ng.h.mL-1 at the two dose levels.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[h·ng] / [ml],136,40946,DB00877,Sirolimus
,19584690,trough level,"In a 12-month multicenter open-label study, cardiac transplant patients received everolimus (trough level 3-8 ng/mL) with reduced cyclosporine A (CsA) or MMF (3 g/day) with standard CsA, both with corticosteroids+/-induction therapy.",Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19584690/),[ng] / [ml],3-8,42949,DB00877,Sirolimus
,23211938,terminal half-life,"The terminal half-life estimate of ridaforolimus (QD × 5 40 mg) was 42.0 h, and the mean half-life ∼30-60 h.",Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23211938/),h,42.0,43191,DB00877,Sirolimus
∼30,23211938,half-life,"The terminal half-life estimate of ridaforolimus (QD × 5 40 mg) was 42.0 h, and the mean half-life ∼30-60 h.",Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23211938/),h,-,43192,DB00877,Sirolimus
∼30,23211938,half-life,"The terminal half-life estimate of ridaforolimus (QD × 5 40 mg) was 42.0 h, and the mean half-life ∼30-60 h.",Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23211938/),h,60,43193,DB00877,Sirolimus
,23211938,clinical benefit rate,"The clinical benefit rate, (complete response, partial response, or stable disease for ≥4 months was 24.5% for all patients and 27.1% for patients with sarcoma.",Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23211938/),,24,43194,DB00877,Sirolimus
,19016466,blood concentration,The highest Biolimus A9 blood concentration measured in any sample was 32.2 pg/mL.,The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19016466/),[pg] / [ml],32.2,44582,DB00877,Sirolimus
,19016466,time to maximum concentration,"The median time to maximum concentration was 2 hr, ranging from 0.05 hr to 3 months.",The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19016466/),h,2,44583,DB00877,Sirolimus
,19016466,time to maximum concentration,"The median time to maximum concentration was 2 hr, ranging from 0.05 hr to 3 months.",The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19016466/),month,3,44584,DB00877,Sirolimus
,24013904,progression-free survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,11.0,45577,DB00877,Sirolimus
,24013904,overall survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,21.0,45578,DB00877,Sirolimus
,22669570,area under the curve (AUC(0-∞)),"The geometric mean (95 % confidence interval, CI) fasted blood area under the curve (AUC(0-∞)) and maximum concentration (C(max)) were 1940 (1510, 2500) ng h/mL and 116 (87, 156) ng/mL, respectively, and median time to C(max) (T(max)) and average apparent terminal half-life (t(1/2)) were 6.0 and 64.5 h, respectively.",The minimal impact of food on the pharmacokinetics of ridaforolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669570/),[h·ng] / [ml],1940,45847,DB00877,Sirolimus
,22669570,maximum concentration (C(max)),"The geometric mean (95 % confidence interval, CI) fasted blood area under the curve (AUC(0-∞)) and maximum concentration (C(max)) were 1940 (1510, 2500) ng h/mL and 116 (87, 156) ng/mL, respectively, and median time to C(max) (T(max)) and average apparent terminal half-life (t(1/2)) were 6.0 and 64.5 h, respectively.",The minimal impact of food on the pharmacokinetics of ridaforolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669570/),[ng] / [ml],116,45848,DB00877,Sirolimus
,22669570,time to C(max) (T(max)),"The geometric mean (95 % confidence interval, CI) fasted blood area under the curve (AUC(0-∞)) and maximum concentration (C(max)) were 1940 (1510, 2500) ng h/mL and 116 (87, 156) ng/mL, respectively, and median time to C(max) (T(max)) and average apparent terminal half-life (t(1/2)) were 6.0 and 64.5 h, respectively.",The minimal impact of food on the pharmacokinetics of ridaforolimus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669570/),h,6.0,45849,DB00877,Sirolimus
,22669570,apparent terminal half-life (t(1/2)),"The geometric mean (95 % confidence interval, CI) fasted blood area under the curve (AUC(0-∞)) and maximum concentration (C(max)) were 1940 (1510, 2500) ng h/mL and 116 (87, 156) ng/mL, respectively, and median time to C(max) (T(max)) and average apparent terminal half-life (t(1/2)) were 6.0 and 64.5 h, respectively.",The minimal impact of food on the pharmacokinetics of ridaforolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669570/),h,64.5,45850,DB00877,Sirolimus
,19784839,T/C,Maximal antitumor effects (T/C of 0.04-0.35) were observed in both species after daily administration with similar C(max) and AUC values of unbound (free) RAD001.,Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19784839/),,0.04-0.35,46054,DB00877,Sirolimus
,22662868,half-time (t(1/2)),"In clinical studies, the highest blood levels were <2 ng/mL at day 2, and half-time (t(1/2)) was 8-9 days.",Tolerability and pharmacokinetics of intravitreal sirolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22662868/),d,8-9,47190,DB00877,Sirolimus
,17020981,Terminal half-life,Terminal half-life was 13 to 25 hours.,A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17020981/),h,13 to 25,47720,DB00877,Sirolimus
,17020981,exposure ratios,Sirolimus-to-temsirolimus exposure ratios were 0.6 to 1.8.,A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17020981/),,0.6 to 1.8,47721,DB00877,Sirolimus
,20975068,progression-free survival,"Median progression-free survival was 34 weeks (95% CI, 29.1 to 40.7 weeks).",Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20975068/),weeks,34,48656,DB00877,Sirolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,21.2,49545,DB00877,Sirolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,19.3,49546,DB00877,Sirolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,14.1,49547,DB00877,Sirolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,12.7,49548,DB00877,Sirolimus
,15084173,half-life,"During this period, SRL half-life increased significantly, from 11.2 +/- 1.0-20.1 +/- 3.1 h (n = 4; p = 0.02).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,11.2,49549,DB00877,Sirolimus
,15084173,half-life,"During this period, SRL half-life increased significantly, from 11.2 +/- 1.0-20.1 +/- 3.1 h (n = 4; p = 0.02).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,20.1,49550,DB00877,Sirolimus
,15084173,half-life,"After introduction of SRL, TAC half-life did not change (11.6 +/- 3.9-14.0 +/- 10.4, n = 10, P = 0.52) in all the groups analyzed together.",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,11.6,49551,DB00877,Sirolimus
,15084173,half-life,"After introduction of SRL, TAC half-life did not change (11.6 +/- 3.9-14.0 +/- 10.4, n = 10, P = 0.52) in all the groups analyzed together.",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,14.0,49552,DB00877,Sirolimus
,15084173,AUC/dose/BSA,TAC AUC/dose/BSA decreased significantly in LTx and SBTx patients (90.9 +/- 55.3 vs. 48.8 +/- 27.3).,Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,90.9,49553,DB00877,Sirolimus
,15084173,AUC/dose/BSA,TAC AUC/dose/BSA decreased significantly in LTx and SBTx patients (90.9 +/- 55.3 vs. 48.8 +/- 27.3).,Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,48.8,49554,DB00877,Sirolimus
,32005746,progression-free survival,The median progression-free survival and overall survival were 2.7 (1.8-4.2) and 9 (6.4-13.2) months.,"A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32005746/),month,2.7,49767,DB00877,Sirolimus
,32005746,overall survival,The median progression-free survival and overall survival were 2.7 (1.8-4.2) and 9 (6.4-13.2) months.,"A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32005746/),month,9,49768,DB00877,Sirolimus
,24861504,trough levels [C0],"Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0] 3-8 ng/mL and 5-15 ng/mL, respectively).","Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861504/),[ng] / [ml],3-8,50425,DB00877,Sirolimus
,24861504,trough levels [C0],"Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0] 3-8 ng/mL and 5-15 ng/mL, respectively).","Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861504/),[ng] / [ml],5-15,50426,DB00877,Sirolimus
,11557912,absorption rate constant,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),1/[h],6.07,52477,DB00877,Sirolimus
,11557912,apparent clearance,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),[l] / [h],8.8,52478,DB00877,Sirolimus
,11557912,apparent central distribution volume,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),l,110,52479,DB00877,Sirolimus
,16236048,AUC((0-24 h)),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1040,52517,DB00877,Sirolimus
,16236048,C(max),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],109,52518,DB00877,Sirolimus
,16236048,AUC((0-24 h)),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1060,52519,DB00877,Sirolimus
,16236048,C(max),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],107,52520,DB00877,Sirolimus
,26181632,half-life,Subcutaneously administered EC0565 in rats displayed good bioavailability and a relatively long half-life (~12 h).,Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26181632/),h,12,53303,DB00877,Sirolimus
,20305057,terminal half-life,"BA9 had a terminal half-life of 90.0 ± 40.0 hours (all n = 21, mean ± standard deviation), an apparent clearance from blood of 0.96 ± 1.07 L/kg/h, and a volume of distribution of 96.5 ± 72.6 L/kg.","Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305057/),h,90.0,54950,DB00877,Sirolimus
,20305057,apparent clearance from blood,"BA9 had a terminal half-life of 90.0 ± 40.0 hours (all n = 21, mean ± standard deviation), an apparent clearance from blood of 0.96 ± 1.07 L/kg/h, and a volume of distribution of 96.5 ± 72.6 L/kg.","Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305057/),[l] / [h·kg],0.96,54951,DB00877,Sirolimus
,20305057,volume of distribution,"BA9 had a terminal half-life of 90.0 ± 40.0 hours (all n = 21, mean ± standard deviation), an apparent clearance from blood of 0.96 ± 1.07 L/kg/h, and a volume of distribution of 96.5 ± 72.6 L/kg.","Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305057/),[l] / [kg],96.5,54952,DB00877,Sirolimus
,27206639,MTD,The MTD of everolimus in combination with cisplatin and radiotherapy has been defined as 5 mg/day.,A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206639/),[mg] / [d],5,55818,DB00877,Sirolimus
,25103371,area under the curve,"Patients received carboplatin (area under the curve = 2 mg/ml/min; 3 weeks on, 1 week off), cetuximab (with a loading dose of 400 mg/m(2) and then 250 mg/m(2) weekly), and dose-escalating everolimus (2.5, 5.0, 7.5, and 10 mg/day) with a 3+3 design.",Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),[mg] / [min·ml],2,56266,DB00877,Sirolimus
,25103371,objective response rate (RR),The objective response rate (RR) was 61.5% (all partial responses).,Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),%,61,56267,DB00877,Sirolimus
,25103371,Progression-free survival (PFS),Progression-free survival (PFS) was 8.15 months.,Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103371/),month,8.15,56268,DB00877,Sirolimus
,23953523,Acute rejection rates,Acute rejection rates were 17.5% with rTAC and 7.7% with sTAC (P = .095).,"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23953523/),%,17.5,58371,DB00877,Sirolimus
,23953523,Acute rejection rates,Acute rejection rates were 17.5% with rTAC and 7.7% with sTAC (P = .095).,"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23953523/),%,7.7,58372,DB00877,Sirolimus
,30956975,extraction recoveries,"The matrix effects and extraction recoveries of sirolimus ranged from 144% to 152% and from 80% to 96%, respectively.",The Effect of Tanreqing Injection on the Pharmacokinetics of Sirolimus in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956975/),%,152,60555,DB00877,Sirolimus
,30956975,extraction recoveries,"The matrix effects and extraction recoveries of sirolimus ranged from 144% to 152% and from 80% to 96%, respectively.",The Effect of Tanreqing Injection on the Pharmacokinetics of Sirolimus in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956975/),%,80,60556,DB00877,Sirolimus
,30956975,extraction recoveries,"The matrix effects and extraction recoveries of sirolimus ranged from 144% to 152% and from 80% to 96%, respectively.",The Effect of Tanreqing Injection on the Pharmacokinetics of Sirolimus in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956975/),%,96,60557,DB00877,Sirolimus
,21177764,time on study,Median time on study was 104 days (range 17-300).,Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177764/),d,104,60784,DB00877,Sirolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.67,60927,DB00877,Sirolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,1.36,60928,DB00877,Sirolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),10,0.42,60929,DB00877,Sirolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.84,60930,DB00877,Sirolimus
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],106.8,60931,DB00877,Sirolimus
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],133.3,60932,DB00877,Sirolimus
,23131698,apparent clearance,Estimation of EVE apparent clearance (3.33 ± 0.20 L/h) and apparent volume of distribution (146 ± 33 L) were in accordance with previously published data.,"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23131698/),[l] / [h],3.33,60994,DB00877,Sirolimus
,23131698,apparent volume of distribution,Estimation of EVE apparent clearance (3.33 ± 0.20 L/h) and apparent volume of distribution (146 ± 33 L) were in accordance with previously published data.,"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23131698/),l,146,60995,DB00877,Sirolimus
,19426700,t(1/2),The elimination half-life was comparable (t(1/2)=5.3h vs. t(1/2)=4h).,Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19426700/),h,5.3,61757,DB00877,Sirolimus
,19426700,t(1/2),The elimination half-life was comparable (t(1/2)=5.3h vs. t(1/2)=4h).,Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19426700/),h,4,61758,DB00877,Sirolimus
,28205374,trough concentration,Dose requirements to attain predefined target trough concentration ranges (10-15 and 5-10 ng/ml) were simulated across the different age groups.,Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205374/),[ng] / [ml],10-15,62517,DB00877,Sirolimus
,28205374,trough concentration,Dose requirements to attain predefined target trough concentration ranges (10-15 and 5-10 ng/ml) were simulated across the different age groups.,Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28205374/),[ng] / [ml],5-10,62518,DB00877,Sirolimus
,21079958,progression-free survival (PFS),Median progression-free survival (PFS) for the doublet therapy was 6.0 months (0.5 to 32+ months) and 5.5 months (0.8 to 27+ months) for the triplet therapy.,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),month,6.0,63224,DB00877,Sirolimus
,21079958,progression-free survival (PFS),Median progression-free survival (PFS) for the doublet therapy was 6.0 months (0.5 to 32+ months) and 5.5 months (0.8 to 27+ months) for the triplet therapy.,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),month,5.5,63225,DB00877,Sirolimus
,21079958,Systemic exposure,Systemic exposure of everolimus was significantly higher in combination with erlotinib (476 ± 161 ng h/mL) compared to when given alone (393 ± 156 ng h/mL; P = 0.020).,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),[h·ng] / [ml],476,63226,DB00877,Sirolimus
,21079958,Systemic exposure,Systemic exposure of everolimus was significantly higher in combination with erlotinib (476 ± 161 ng h/mL) compared to when given alone (393 ± 156 ng h/mL; P = 0.020).,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079958/),[h·ng] / [ml],393,63227,DB00877,Sirolimus
,9013365,peak plasma concentration (Cmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[ng] / [ml],187,64277,DB00877,Sirolimus
,9013365,time to peak plasma concentration (tmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,2.03,64278,DB00877,Sirolimus
,9013365,rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),1/[h],0.149,64279,DB00877,Sirolimus
,9013365,terminal half-life (t1/2),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,3.60,64280,DB00877,Sirolimus
,9013365,AUC,Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[h·ng] / [ml],1206,64281,DB00877,Sirolimus
,9013365,apparent clearance (Cl/F),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[l] / [h·kg],0.094,64282,DB00877,Sirolimus
,26174223,time receiving drug,Mean time receiving drug was 99 days.,A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26174223/),d,99,65360,DB00877,Sirolimus
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.20,67246,DB00877,Sirolimus
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.25,67247,DB00877,Sirolimus
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.44,67248,DB00877,Sirolimus
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],43.1,67746,DB00877,Sirolimus
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],0.394,67747,DB00877,Sirolimus
,26375845,AUC,Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients.,"Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),,4,67934,DB00877,Sirolimus
,26375845,time to progression,"The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months).","Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),month,2.5,67935,DB00877,Sirolimus
,26375845,overall survival,"The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months).","Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),month,12.5,67936,DB00877,Sirolimus
,15955899,objective response rate,Temsirolimus produced an objective response rate of 9.2% (10 partial responses) in the intent-to-treat population.,"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955899/),%,9.2,69976,DB00877,Sirolimus
,15955899,time to tumor progression,Median time to tumor progression was 12.0 weeks.,"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955899/),weeks,12.0,69977,DB00877,Sirolimus
,26951309,progression-free survival,"After 67 events, stratified analysis revealed that median progression-free survival was significantly shorter for apitolisib than for everolimus (3.7 v 6.1 months; hazard ratio, 2.12 [95% CI, 1.23 to 3.63; P < .01]); apitolisib was not favored in any stratification subgroup.","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,3.7,70597,DB00877,Sirolimus
,26951309,progression-free survival,"After 67 events, stratified analysis revealed that median progression-free survival was significantly shorter for apitolisib than for everolimus (3.7 v 6.1 months; hazard ratio, 2.12 [95% CI, 1.23 to 3.63; P < .01]); apitolisib was not favored in any stratification subgroup.","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,6.1,70598,DB00877,Sirolimus
,26951309,overall survival,"Median overall survival was not significantly different but trended in favor of everolimus (16.5 v 22.8 months; hazard ratio, 1.77 [95% CI, 0.97 to 3.24; P = .06]).","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,16.5,70599,DB00877,Sirolimus
,26951309,overall survival,"Median overall survival was not significantly different but trended in favor of everolimus (16.5 v 22.8 months; hazard ratio, 1.77 [95% CI, 0.97 to 3.24; P = .06]).","Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),month,22.8,70600,DB00877,Sirolimus
,26951309,objective response rate,The objective response rate was 7.1% for apitolisib and 11.6% for everolimus.,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),%,7.1,70601,DB00877,Sirolimus
,26951309,objective response rate,The objective response rate was 7.1% for apitolisib and 11.6% for everolimus.,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26951309/),%,11.6,70602,DB00877,Sirolimus
,26714164,central volume of distribution,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),l,2.1,72701,DB00877,Sirolimus
,26714164,peripheral volume of distribution,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),l,1.3,72702,DB00877,Sirolimus
,26714164,intercompartment clearance,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),[l] / [day],0.36,72703,DB00877,Sirolimus
,26714164,elimination half-life,"Estimated parameters (interindiviual standard deviation) were central volume of distribution =2.1 l (23%), peripheral volume of distribution =1.3 l (38%), intercompartment clearance =0.36 l day(-1) , with an elimination half-life of 11.8 days.",Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),d,11.8,72704,DB00877,Sirolimus
,26714164,clearance,Typical clearance was 0.22 l day(-1) (19%) and its value was increased with tumour size.,Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26714164/),[l] / [day],0.22,72705,DB00877,Sirolimus
,16195616,total restenosis rate,The total restenosis rate was 10% (3 lesions) and target vessel revascularization was performed in those 3 cases (15%).,Angiographic and clinical outcomes of a pharmacokinetic study of sirolimus-eluting stents: lesson from restenosis cases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16195616/),%,10,76171,DB00877,Sirolimus
,17947729,clearance,"At the MTD of 5 mg/m2, the median everolimus clearance was 15.2 L/h/m2, with a plasma everolimus concentration-time area under the curve (AUC) from 0 to infinity of 239.6 ng/mL x h.",Phase I study of everolimus in pediatric patients with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947729/),[l] / [h·m2],15.2,76924,DB00877,Sirolimus
,17947729,concentration-time area under the curve (AUC) from 0 to infinity,"At the MTD of 5 mg/m2, the median everolimus clearance was 15.2 L/h/m2, with a plasma everolimus concentration-time area under the curve (AUC) from 0 to infinity of 239.6 ng/mL x h.",Phase I study of everolimus in pediatric patients with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947729/),[ng] / [h·ml],239.6,76925,DB00877,Sirolimus
,17947729,AUCs,"Significant inhibition of mTOR pathway signaling was observed in PBMCs from patients achieving AUCs 200 ng/mL x h, equivalent to dosages of 3 to 5 mg/m2 of everolimus.",Phase I study of everolimus in pediatric patients with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947729/),[ng] / [h·ml],200,76926,DB00877,Sirolimus
,32335374,t1/2z,"Single dosing of vorolanib demonstrated dose-proportional increases in the Cmax and AUC, and observed short t1/2z ranging from 4.74±1.44 to 12.89±7.49 h.",Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32335374/),h,4.74,77239,DB00877,Sirolimus
,32335374,t1/2z,"Single dosing of vorolanib demonstrated dose-proportional increases in the Cmax and AUC, and observed short t1/2z ranging from 4.74±1.44 to 12.89±7.49 h.",Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32335374/),h,12.89,77240,DB00877,Sirolimus
,31376625,trough EVR level,The trough EVR level in both groups was maintained within 3-8 ng/mL during the perioperative period.,Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376625/),[ng] / [ml],3-8,78330,DB00877,Sirolimus
,21168674,time after transplantation,"Mean patient age was 58.2 ± 8.8 years, and mean time after transplantation was 2.3 ± 4.0 years (range, 0.2-13.0 years).",Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),years,2.3,78356,DB00877,Sirolimus
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.5,78357,DB00877,Sirolimus
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.8,78358,DB00877,Sirolimus
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],45.2,78359,DB00877,Sirolimus
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],65.2,78360,DB00877,Sirolimus
,31752553,en,"The average particle size of the micelles was (8.74 ± 0.21) nm, the encapsulation efficiency and drug loading were (90.12 ± 1.18)% and (2.14 ± 0.028)%, while the average particle size of the nanosuspension was (156.47 ± 1.10) nm, and the drug loading was (16.51 ± 0.21)%, respectively.",Preparation and study of two kinds of ophthalmic nano-preparations of everolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31752553/),%,90.12,79170,DB00877,Sirolimus
,31752553,particle size,"The average particle size of the micelles was (8.74 ± 0.21) nm, the encapsulation efficiency and drug loading were (90.12 ± 1.18)% and (2.14 ± 0.028)%, while the average particle size of the nanosuspension was (156.47 ± 1.10) nm, and the drug loading was (16.51 ± 0.21)%, respectively.",Preparation and study of two kinds of ophthalmic nano-preparations of everolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31752553/),,156.,79171,DB00877,Sirolimus
,17096757,trough levels,SRL was dosed to achieve target trough levels between 10 and 20 ng/mL.,Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17096757/),[ng] / [ml],10 and 20,81471,DB00877,Sirolimus
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],3 and 15,83849,DB00877,Sirolimus
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],100-300,83850,DB00877,Sirolimus
,27095353,Aerodynamic diameters,Aerodynamic diameters of formulations were 0.7-4.7 μm.,Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095353/),μm,0.7-4.7,85049,DB00877,Sirolimus
,27095353,AUC0-48,"Inhaled particles reached deep lungs and were phagocytosed by alveolar macrophages, yielding AUC0-48 of 102 compared to 0.1 μg/ml × h obtained with equivalent intravenous dose.",Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095353/),[μg] / [h·ml],102,85050,DB00877,Sirolimus
,27095353,AUC0-48,"Inhaled particles reached deep lungs and were phagocytosed by alveolar macrophages, yielding AUC0-48 of 102 compared to 0.1 μg/ml × h obtained with equivalent intravenous dose.",Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095353/),[μg] / [h·ml],0.1,85051,DB00877,Sirolimus
,19662626,flow rate,"Mobile phase contains acetonitrile, water (80; 20 v/v) + 0.1% acetic acid, flow rate 1 mL/min.",Liquid chromatography-tandem mass spectrometry method for determination of Sirolimus coated drug eluting nano porous carbon stents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19662626/),[ml] / [min],1,86099,DB00877,Sirolimus
,19662626,retention time,"The retention time of Sirolimus 8.4 min, the total run time10 min.",Liquid chromatography-tandem mass spectrometry method for determination of Sirolimus coated drug eluting nano porous carbon stents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19662626/),min,8.4,86100,DB00877,Sirolimus
,19662626,total run time,"The retention time of Sirolimus 8.4 min, the total run time10 min.",Liquid chromatography-tandem mass spectrometry method for determination of Sirolimus coated drug eluting nano porous carbon stents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19662626/),min,10,86101,DB00877,Sirolimus
,16160599,half-lives,"Peak concentrations were observed approximately 4 hours after the SES implantation, and sirolimus half-lives were approximately 120 hours in each group.",Comparison of pharmacokinetics of the sirolimus-eluting stent in Japanese patients with those in American patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16160599/),h,120,87725,DB00877,Sirolimus
,16160599,peak sirolimus levels,"Mean peak sirolimus levels were 0.86 and 2.00 ng/mL for the group 1 and group 2, respectively.",Comparison of pharmacokinetics of the sirolimus-eluting stent in Japanese patients with those in American patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16160599/),[ng] / [ml],0.86,87726,DB00877,Sirolimus
,16160599,peak sirolimus levels,"Mean peak sirolimus levels were 0.86 and 2.00 ng/mL for the group 1 and group 2, respectively.",Comparison of pharmacokinetics of the sirolimus-eluting stent in Japanese patients with those in American patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16160599/),[ng] / [ml],2.00,87727,DB00877,Sirolimus
,8878394,mean survival time (MST),"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,6.4,89831,DB00877,Sirolimus
,8878394,mean survival time (MST),"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,12.3,89832,DB00877,Sirolimus
,8878394,MST,"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,18.0,89833,DB00877,Sirolimus
,8878394,MST,"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,52.5,89834,DB00877,Sirolimus
,8878394,MST,"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,90.0,89835,DB00877,Sirolimus
less,8878394,oral bioavailability,Comparison of the in vivo effects after oral versus continuous intravenous SRL administration suggested that the oral bioavailability of SRL is less than 10%.,Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),%,10,89836,DB00877,Sirolimus
,8878394,ED50,"The ED50 for SRL alone is 2.4 mg/kg per day, which produces an average [SRL(WB)] of 13.2 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[mg] / [d·kg],2.4,89837,DB00877,Sirolimus
,8878394,[,"The ED50 for SRL alone is 2.4 mg/kg per day, which produces an average [SRL(WB)] of 13.2 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],13.2,89838,DB00877,Sirolimus
,8878394,SRL(WB)],"The ED50 for SRL alone is 2.4 mg/kg per day, which produces an average [SRL(WB)] of 13.2 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],13.2,89839,DB00877,Sirolimus
,8878394,ED50,"The ED50 for CsA alone is 8.0 mg/kg per day, which produces an average [CsA(WB)] of 1642 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[mg] / [d·kg],8.0,89840,DB00877,Sirolimus
,8878394,ED50,"However, when the two drugs are combined, the ED50 effect is achieved with only 0.34 mg/kg SRL per day ([SRL(WB)]=1.1 ng/ml) and 2.1 mg/kg CsA per day ([CsA(WB)] =326 ng/ml).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],1.1,89841,DB00877,Sirolimus
,8878394,ED50,"However, when the two drugs are combined, the ED50 effect is achieved with only 0.34 mg/kg SRL per day ([SRL(WB)]=1.1 ng/ml) and 2.1 mg/kg CsA per day ([CsA(WB)] =326 ng/ml).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],326,89842,DB00877,Sirolimus
,8878394,SRL,"Individually, 0.34 mg/kg SRL per day produces an ED9 with an average [SRL(WB)] of 0.6 ng/ml, and 2.1 mg/kg CsA per day produces an ED22 with an average [CsA(WB)] of 174 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),,0,89843,DB00877,Sirolimus
,33356170,mean residence time (MRT),"Intra-LG injection with the depot formulation (5FV) retained Rapa in the LG for a mean residence time (MRT) of 75.6 h compared to Rapa delivery complexed with a soluble carrier control (5FA), which had a MRT of 11.7 h in the LG.",Intralacrimal Sustained Delivery of Rapamycin Shows Therapeutic Effects without Systemic Toxicity in a Mouse Model of Autoimmune Dacryoadenitis Characteristic of Sjögren's Syndrome. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356170/),h,75.6,92234,DB00877,Sirolimus
,33356170,MRT,"Intra-LG injection with the depot formulation (5FV) retained Rapa in the LG for a mean residence time (MRT) of 75.6 h compared to Rapa delivery complexed with a soluble carrier control (5FA), which had a MRT of 11.7 h in the LG.",Intralacrimal Sustained Delivery of Rapamycin Shows Therapeutic Effects without Systemic Toxicity in a Mouse Model of Autoimmune Dacryoadenitis Characteristic of Sjögren's Syndrome. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356170/),h,11.7,92235,DB00877,Sirolimus
,8281627,total plasma clearance,"RG exhibited dose-dependent pharmacokinetics, characterized by an increase in the total plasma clearance from 12.5 to 39.3 ml.","Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281627/),ml,12.5,92945,DB00877,Sirolimus
,8281627,total plasma clearance,"RG exhibited dose-dependent pharmacokinetics, characterized by an increase in the total plasma clearance from 12.5 to 39.3 ml.","Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281627/),ml,39.3,92946,DB00877,Sirolimus
,8281627,biological half-life,"The terminal rate constants decreased linearly as the dose was increased from 10 to 100 mg/kg, eliciting an apparent prolongation of the biological half-life from 2.1 to 4.8 h.","Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281627/),h,2.1,92947,DB00877,Sirolimus
,8281627,biological half-life,"The terminal rate constants decreased linearly as the dose was increased from 10 to 100 mg/kg, eliciting an apparent prolongation of the biological half-life from 2.1 to 4.8 h.","Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281627/),h,4.8,92948,DB00877,Sirolimus
,8281627,steady state apparent volume of distribution,There was also a sequential increase in the steady state apparent volume of distribution from 1.73 to 8.75 l/kg.,"Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281627/),[l] / [kg],1.73,92949,DB00877,Sirolimus
,8281627,steady state apparent volume of distribution,There was also a sequential increase in the steady state apparent volume of distribution from 1.73 to 8.75 l/kg.,"Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281627/),[l] / [kg],8.75,92950,DB00877,Sirolimus
,15183289,trough concentrations,"In maintenance adult patients after conversion to a calcineurin inhibitor-free regimen, sirolimus trough concentrations of 5-10 microg/l are proposed in combination with mycophenolate mofetil.",Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15183289/),[μg] / [l],5-10,93468,DB00877,Sirolimus
,15256815,blood trough levels,Administration of a low dosis of sirolimus (1 mg/day) led to relevant sirolimus (4.16 +/- 1.85 ng/ml) and MMF blood trough levels (month 1: 6.8 +/- 3.46; month 3: 4.67 +/- 1.78 mg/l).,Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15256815/),[mg] / [l],6.8,95575,DB00877,Sirolimus
,15256815,blood trough levels,Administration of a low dosis of sirolimus (1 mg/day) led to relevant sirolimus (4.16 +/- 1.85 ng/ml) and MMF blood trough levels (month 1: 6.8 +/- 3.46; month 3: 4.67 +/- 1.78 mg/l).,Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15256815/),[mg] / [l],4.67,95576,DB00877,Sirolimus
,27169792,AUC0-24,"Patients who required a dose reduction (n = 18) due to toxicity at any time during treatment had significant higher everolimus exposures [mean AUC0-24 (SD) 600 (274) vs. 395 (129) µg h/L, P = 0.008] than patients without a dose reduction (n = 22).",Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169792/),[h·μg] / [l],600,96778,DB00877,Sirolimus
,27169792,AUC0-24,"Patients who required a dose reduction (n = 18) due to toxicity at any time during treatment had significant higher everolimus exposures [mean AUC0-24 (SD) 600 (274) vs. 395 (129) µg h/L, P = 0.008] than patients without a dose reduction (n = 22).",Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169792/),[h·μg] / [l],395,96779,DB00877,Sirolimus
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,50.0,98403,DB00877,Sirolimus
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,22.2,98404,DB00877,Sirolimus
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,16.7,98405,DB00877,Sirolimus
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,40.0,98406,DB00877,Sirolimus
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,61.1,98407,DB00877,Sirolimus
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,58.3,98408,DB00877,Sirolimus
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],8 and 12,98662,DB00877,Sirolimus
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],15 to 20,98663,DB00877,Sirolimus
,12742493,late loss,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),mm,0.56,98664,DB00877,Sirolimus
,12742493,loss index,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),,0.33,98665,DB00877,Sirolimus
,23099651,PFS,Median PFS was 8 weeks.,Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099651/),,8,102403,DB00877,Sirolimus
,25223651,blood concentration,The highest sirolimus blood concentration was 105 pg/mL.,Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223651/),[pg] / [ml],105,103634,DB00877,Sirolimus
,25223651,maximum concentration,The median maximum concentration was 36.8 pg/mL (range 22.9-41.5 pg/mL) for stent 3.0 × 15 mm and 87.2 pg/mL (range 60.0-105.0 pg/mL) for 3 × 28 mm stent.,Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223651/),[pg] / [ml],36.8,103635,DB00877,Sirolimus
,25223651,maximum concentration,The median maximum concentration was 36.8 pg/mL (range 22.9-41.5 pg/mL) for stent 3.0 × 15 mm and 87.2 pg/mL (range 60.0-105.0 pg/mL) for 3 × 28 mm stent.,Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223651/),[pg] / [ml],87.2,103636,DB00877,Sirolimus
,25223651,area under the time-concentration curve,"The median systemic exposure, as measured by the area under the time-concentration curve, was 8.3 ng h/mL (range 6.47-28.0 ng h/mL).",Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223651/),[h·ng] / [ml],8.3,103637,DB00877,Sirolimus
,17175302,trough level (C0),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],7.9,103909,DB00877,Sirolimus
,17175302,area under the curve over a dosing interval (AUC),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],132,103910,DB00877,Sirolimus
,17175302,C0,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.4,103911,DB00877,Sirolimus
,17175302,AUC,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],134,103912,DB00877,Sirolimus
,17175302,C0,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.3,103913,DB00877,Sirolimus
,17175302,Cmax,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],10.4,103914,DB00877,Sirolimus
,17175302,AUC,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],58,103915,DB00877,Sirolimus
,17175302,C0,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.0,103916,DB00877,Sirolimus
,17175302,Cmax,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.2,103917,DB00877,Sirolimus
,17175302,AUC,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],49,103918,DB00877,Sirolimus
,33514567,Peak serum rapamycin concentration,Peak serum rapamycin concentration was 7.1 ng/mL after a 1 mg dose.,Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33514567/),[ng] / [ml],7.1,104258,DB00877,Sirolimus
,33514567,trough levels,Stable trough levels (∼2 ng/mL) developed after 48-72 hours.,Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33514567/),[ng] / [ml],∼2,104259,DB00877,Sirolimus
,22182476,time to platelet recovery,RAD001/CsA caused a more pronounced reduction of platelet counts to median 2 × 10(9)/L (range: 0-21 × 10(9)/L) and longer time to platelet recovery of 21 days (range: 14-24 days) compared with MMF/CsA.,Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22182476/),d,21,105054,DB00877,Sirolimus
,18332470,Terminal half-life,"Terminal half-life was 30 hours (range, 26 to 38 hours).",Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18332470/),h,30,106887,DB00877,Sirolimus
,12829916,C(min) (trough level),"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],4.7,107786,DB00877,Sirolimus
,12829916,peak concentration,"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],13.5,107787,DB00877,Sirolimus
,12829916,area under the concentration-time curve (AUC),"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[h·ng] / [ml],77,107788,DB00877,Sirolimus
,12829916,apparent oral clearance,"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[l] / [h·m2],10.2,107789,DB00877,Sirolimus
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.9,107790,DB00877,Sirolimus
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.4,107791,DB00877,Sirolimus
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.1,107792,DB00877,Sirolimus
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],156,107793,DB00877,Sirolimus
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],83,107794,DB00877,Sirolimus
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],69,107795,DB00877,Sirolimus
,20155737,CL/F,Fast metabolizers (expressers) had a CL/F of 28.3 l/h whilst slow metabolizers (non-expressers) had a CL/F of 14.1 l/h.,Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20155737/),[l] / [h],28.3,113366,DB00877,Sirolimus
,20155737,CL/F,Fast metabolizers (expressers) had a CL/F of 28.3 l/h whilst slow metabolizers (non-expressers) had a CL/F of 14.1 l/h.,Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20155737/),[l] / [h],14.1,113367,DB00877,Sirolimus
,20155737,trough,"Here, in simulation, a standard 10 mg QD SRL was contrasted with a higher frequency of 5 mg BID SRL as related to the proportion of next dosed patients being within the 15-30 ng/ml trough levels on day 7 after transplantation.",Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20155737/),ng,15-30,113368,DB00877,Sirolimus
,22033322,duration of stable disease,"In the three cohorts, median duration of stable disease or better was 128, 663 and 75 d, respectively.","Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22033322/),d,128,113625,DB00877,Sirolimus
,22033322,duration of stable disease,"In the three cohorts, median duration of stable disease or better was 128, 663 and 75 d, respectively.","Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22033322/),d,663,113626,DB00877,Sirolimus
,22033322,duration of stable disease,"In the three cohorts, median duration of stable disease or better was 128, 663 and 75 d, respectively.","Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22033322/),d,75,113627,DB00877,Sirolimus
,19015855,K(i),"In vitro studies with pooled human liver microsomes showed that temsirolimus and its principal metabolite, sirolimus, inhibit the CYP2D6 isozyme (K(i) = 1.5 and 5 microM, respectively), indicating potential for pharmacokinetic interaction with agents that are substrates of CYP2D6.","Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015855/),μM,1.5,114042,DB00877,Sirolimus
,19015855,K(i),"In vitro studies with pooled human liver microsomes showed that temsirolimus and its principal metabolite, sirolimus, inhibit the CYP2D6 isozyme (K(i) = 1.5 and 5 microM, respectively), indicating potential for pharmacokinetic interaction with agents that are substrates of CYP2D6.","Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015855/),μM,5,114043,DB00877,Sirolimus
,22624503,area under the blood concentration-time curve from time zero to 12 hours (AUC(12)),Everolimus blood concentrations were analysed in whole blood using liquid chromatography-tandem mass spectrometry during routine therapeutic drug monitoring targeting an area under the blood concentration-time curve from time zero to 12 hours (AUC(12)) of 120 μg · h/L.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114932,DB00877,Sirolimus
,22624503,AUC(12),Maintaining everolimus systemic exposure at an AUC(12) of 120 μg · h/L resulted in low rejection rates but considerable numbers of adverse events and toxicity.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114933,DB00877,Sirolimus
,22624503,oral clearance,Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[l] / [h],17.9,114934,DB00877,Sirolimus
,22624503,volume of distribution of the central compartment after oral administration [V(1)/F],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),l,148,114935,DB00877,Sirolimus
,22624503,first-order absorption rate constant [k(a)],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),1/[h],7.36,114936,DB00877,Sirolimus
,11034268,analytical recovery,"At the limit of quantification (0.25 microg/L), for both sirolimus and tacrolimus, the interday imprecision was < 3% and the analytical recovery was between 97.0% and 102%, respectively.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,97.0,116587,DB00877,Sirolimus
,11034268,analytical recovery,"At the limit of quantification (0.25 microg/L), for both sirolimus and tacrolimus, the interday imprecision was < 3% and the analytical recovery was between 97.0% and 102%, respectively.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,102,116588,DB00877,Sirolimus
,11034268,analytical recovery,"The analytical recovery, at the three control concentrations, ranged from 99.2% to 104% of the nominal concentration.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,99.2,116589,DB00877,Sirolimus
,11034268,analytical recovery,"The analytical recovery, at the three control concentrations, ranged from 99.2% to 104% of the nominal concentration.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,104,116590,DB00877,Sirolimus
,11034268,absolute recovery,"The mean absolute recovery (+/- standard deviation) of tacrolimus, sirolimus, and internal standard was 82 +/- 7%, 89 +/- 12%, and 77 +/- 8%, respectively (n = 12).","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,82,116591,DB00877,Sirolimus
,11034268,absolute recovery,"The mean absolute recovery (+/- standard deviation) of tacrolimus, sirolimus, and internal standard was 82 +/- 7%, 89 +/- 12%, and 77 +/- 8%, respectively (n = 12).","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,89,116592,DB00877,Sirolimus
,11034268,absolute recovery,"The mean absolute recovery (+/- standard deviation) of tacrolimus, sirolimus, and internal standard was 82 +/- 7%, 89 +/- 12%, and 77 +/- 8%, respectively (n = 12).","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,77,116593,DB00877,Sirolimus
,17438408,terminal elimination half-lives,"Rat pharmacokinetic studies with intravenous dosing demonstrated terminal elimination half-lives of 9.4 hours and 14.0 hours for zotarolimus and sirolimus, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,9.4,120010,DB00877,Sirolimus
,17438408,terminal elimination half-lives,"Rat pharmacokinetic studies with intravenous dosing demonstrated terminal elimination half-lives of 9.4 hours and 14.0 hours for zotarolimus and sirolimus, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,14.0,120011,DB00877,Sirolimus
,17438408,T1/2,"Given orally, T1/2 values were 7.9 hours and 33.4 hours, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,7.9,120012,DB00877,Sirolimus
,17438408,T1/2,"Given orally, T1/2 values were 7.9 hours and 33.4 hours, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,33.4,120013,DB00877,Sirolimus
,26919549,concentrations,"In TAC (STN → MPS) group, dose-adjusted TAC concentrations decreased from baseline to first week (2.3 ± 1.1 versus 1.5 ± 1.0 ng·mL·mg, P < 0.05).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),,1.5,121430,DB00877,Sirolimus
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,3.,121431,DB00877,Sirolimus
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,1.9,121432,DB00877,Sirolimus
,33547201,RP2D,"The RP2D of ribociclib and everolimus was 120 and 1.2 mg/m2 for 21 and 28 days, respectively.",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),[mg] / [m2],120,122370,DB00877,Sirolimus
,33547201,RP2D,"The RP2D of ribociclib and everolimus was 120 and 1.2 mg/m2 for 21 and 28 days, respectively.",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),[mg] / [m2],1.2,122371,DB00877,Sirolimus
,33547201,tumor-to-plasma ratio,"The mean tumor-to-plasma ratio of ribociclib was 19.8 (range, 2.22-53.4).",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),,19.8,122372,DB00877,Sirolimus
,24991838,progression-free survival,The median progression-free survival in 13 melanoma patients treated with HCQ 1200mg/d in combination with TEM was 3.5 mo.,Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24991838/),mo,3.5,123535,DB00877,Sirolimus
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],21,126057,DB00877,Sirolimus
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],47,126058,DB00877,Sirolimus
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],115,126059,DB00877,Sirolimus
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],392,126060,DB00877,Sirolimus
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,32,126061,DB00877,Sirolimus
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,37,126062,DB00877,Sirolimus
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126063,DB00877,Sirolimus
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126064,DB00877,Sirolimus
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126065,DB00877,Sirolimus
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126066,DB00877,Sirolimus
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],15,126304,DB00877,Sirolimus
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],180,126305,DB00877,Sirolimus
,23676788,T-bil,"Thereafter, the levels of AST and ALT as well as the T-bil were successfully decreased to 73 U/L, 83 U/L, and 3.0 mg/dL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[mg] / [dl],3.0,126306,DB00877,Sirolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,821.49,127188,DB00877,Sirolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,4768.35,127189,DB00877,Sirolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,931.69,127190,DB00877,Sirolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,864.39,127191,DB00877,Sirolimus
,18074760,absolute recovery,"Method showed to be accurate, precise and linear over the range from 1 to 80 ng/ml, having an absolute recovery of 94%.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),%,94,127192,DB00877,Sirolimus
,18074760,Total run-time,Total run-time is around 1.5 min.,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),min,1.5,127193,DB00877,Sirolimus
,18074760,maximum blood concentration,"Mean maximum blood concentration was 32.63 +/- 1.74 ng/ml, and was reached at 1 h post-dose; elimination half-life was 14.18 +/- 5.71 h.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),[ng] / [ml],32.63,127194,DB00877,Sirolimus
,18074760,elimination half-life,"Mean maximum blood concentration was 32.63 +/- 1.74 ng/ml, and was reached at 1 h post-dose; elimination half-life was 14.18 +/- 5.71 h.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),h,14.18,127195,DB00877,Sirolimus
,22143378,half-life,Ridaforolimus in the whole blood was rapidly absorbed and slowly eliminated with a half-life of approximately 56-58 h after a single dose.,"Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143378/),h,56-58,127954,DB00877,Sirolimus
,23956145,trough concentration,"Sirolimus was administered daily by mouth or nasogastric (NG) tube, with doses adjusted to achieve a target trough concentration of 10-15 ng/ml, with weekly intravenous vinblastine (dose escalated 4-6 mg/m(2)/dose according to 3 + 3 phase I design).",Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23956145/),[ng] / [ml],10-15,128738,DB00877,Sirolimus
,23956145,trough concentrations,Dose-adjusted sirolimus trough concentrations were significantly lower in patients receiving drug via NG tube (1.50 ± 0.75 ng/ml/mg vs. 2.25 ± 1.07 ng/ml/mg for oral administration).,Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23956145/),[ng] / [mg·ml],1.50,128739,DB00877,Sirolimus
,23956145,trough concentrations,Dose-adjusted sirolimus trough concentrations were significantly lower in patients receiving drug via NG tube (1.50 ± 0.75 ng/ml/mg vs. 2.25 ± 1.07 ng/ml/mg for oral administration).,Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23956145/),[ng] / [mg·ml],2.25,128740,DB00877,Sirolimus
,21232120,Tmax,"Everolimus was absorbed rapidly; median Tmax was 3 h (range, 1-4) and 2 h (range, 0.9-6) in the 5 and 10 mg/day groups, respectively.",Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21232120/),h,3,128741,DB00877,Sirolimus
,21232120,Tmax,"Everolimus was absorbed rapidly; median Tmax was 3 h (range, 1-4) and 2 h (range, 0.9-6) in the 5 and 10 mg/day groups, respectively.",Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21232120/),h,2,128742,DB00877,Sirolimus
,25017487,trough concentration,Everolimus exposure is unaffected when tacrolimus exposure is down-titrated within the trough concentration range of 1.5-7 ng/mL.,The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25017487/),[ng] / [ml],1.5-7,130074,DB00877,Sirolimus
,18367972,Sir AUC,The average Sir AUC was 64.9 +/- 29.7 ng*h/mL.,Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],64.9,133309,DB00877,Sirolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],7.6,133310,DB00877,Sirolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.1,133311,DB00877,Sirolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133312,DB00877,Sirolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.5,133313,DB00877,Sirolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.6,133314,DB00877,Sirolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],5.0,133315,DB00877,Sirolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133316,DB00877,Sirolimus
,20040005,C(max),Individual C(max) ranged from 0.17 to 2.40 ng/mL and occurred between 0.07 and 1.88 hours across all dose levels.,Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040005/),[ng] / [ml],0.17 to 2.40,133395,DB00877,Sirolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,150,134028,DB00877,Sirolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,180,134029,DB00877,Sirolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,88,134030,DB00877,Sirolimus
,21538783,Total drug doses,"Total drug doses of the Cypher stent, Endeavor stent, Xience V stent, and Nobori stent were 150, 180, 88, and 293 μg, respectively.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),μg,293,134031,DB00877,Sirolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],0.86,134032,DB00877,Sirolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],1.80,134033,DB00877,Sirolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],0.50,134034,DB00877,Sirolimus
,21538783,peak drug levels,"Mean peak drug levels were 0.86 ng mL(-1) for Cypher, 1.80 ng mL(-1) for Endeavor, 0.50 ng mL(-1) for Xience V, and 0.09 ng mL(-1) for Nobori.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml],0.09,134035,DB00877,Sirolimus
,21538783,peak drug levels,"After adjustment for the loaded dose, mean peak drug levels of the Cypher and Xience V stents were similar (0.0057 ng mL(-1) μg(-1) each) while the Endeavor (0.0100 ng mL(-1) μg(-1)) was higher, and the Nobori (0.0003 ng mL(-1) μg(-1)) was lower, compared with the Cypher and Xience V stents.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml·μg],0.0057,134036,DB00877,Sirolimus
,21538783,peak drug levels,"After adjustment for the loaded dose, mean peak drug levels of the Cypher and Xience V stents were similar (0.0057 ng mL(-1) μg(-1) each) while the Endeavor (0.0100 ng mL(-1) μg(-1)) was higher, and the Nobori (0.0003 ng mL(-1) μg(-1)) was lower, compared with the Cypher and Xience V stents.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml·μg],0.0100,134037,DB00877,Sirolimus
,21538783,peak drug levels,"After adjustment for the loaded dose, mean peak drug levels of the Cypher and Xience V stents were similar (0.0057 ng mL(-1) μg(-1) each) while the Endeavor (0.0100 ng mL(-1) μg(-1)) was higher, and the Nobori (0.0003 ng mL(-1) μg(-1)) was lower, compared with the Cypher and Xience V stents.",Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21538783/),[ng] / [ml·μg],0.0003,134038,DB00877,Sirolimus
,10551636,half-life,"The drug was absorbed within 2 hr and displayed a 16-19-hr half-life, which is shorter than that of rapamycin.",A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551636/),h,16-19-,136171,DB00877,Sirolimus
,16815317,AUC/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,26.6,136172,DB00877,Sirolimus
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,51.1,136173,DB00877,Sirolimus
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,4.8,136174,DB00877,Sirolimus
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,7.7,136175,DB00877,Sirolimus
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,1.5,136176,DB00877,Sirolimus
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,3.0,136177,DB00877,Sirolimus
,16815317,C(0)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,1.5,136178,DB00877,Sirolimus
,16815317,C(0)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,3.0,136179,DB00877,Sirolimus
,12777861,half-life,"Because the subsequent pharmacokinetic analysis indicated rapid everolimus absorption, distribution, and clearance in mice (with a half-life of 3 to 6 hr and maximum drug blood concentration reached after 0.5 to 1 hr), treatment was changed to a twice-daily regimen.",Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12777861/),h,3 to 6,138777,DB00877,Sirolimus
,17431753,clearance rate,Everolimus exhibited a high clearance rate that was limited to the hepatic blood flow (47.2 ml/min/kg).,Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431753/),[ml] / [kg·min],47.2,140070,DB00877,Sirolimus
,17431753,hepatic blood flow,Everolimus exhibited a high clearance rate that was limited to the hepatic blood flow (47.2 ml/min/kg).,Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431753/),[ml] / [kg·min],47.2,140071,DB00877,Sirolimus
,17431753,oral bioavailability,"The oral bioavailability value, as estimated with the PBPK, was 12% and was similar to the value obtained by non-compartmental analysis.",Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431753/),%,12,140072,DB00877,Sirolimus
,22067664,trough concentrations,"Seven participants, 4 on PI-based and 3 on NNRTI-based ART, had rapamycin titrated to achieve trough concentrations of 5-10 ng/mL.",Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22067664/),[ng] / [ml],5-10,142693,DB00877,Sirolimus
,33753454,DFI,"There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively.","Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753454/),d,180,143061,DB00877,Sirolimus
,33753454,DFI,"There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively.","Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753454/),d,282,143062,DB00877,Sirolimus
,33753454,DFI,"There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively.","Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753454/),d,204,143063,DB00877,Sirolimus
,33753454,survival,"There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively.","Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753454/),d,282,143064,DB00877,Sirolimus
,33753454,survival,"There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively.","Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753454/),d,204,143065,DB00877,Sirolimus
,33753454,survival,"There was no significant difference in the median DFI or overall survival between the two arms of this trial; the median DFI and survival for standard-of-care (SOC; defined as amputation and carboplatin therapy) dogs was 180 days [95% confidence interval (CI), 144-237] and 282 days (95% CI, 224-383) and for SOC + sirolimus dogs, it was 204 days (95% CI, 157-217) and 280 days (95% CI, 252-332), respectively.","Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33753454/),d,280,143066,DB00877,Sirolimus
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.4,143176,DB00877,Sirolimus
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.5,143177,DB00877,Sirolimus
,24628014,L/D,There was no significant difference in EVR L/D between ABCB1 CGC diplotype groups (CGC/CGC = 2.4 ± 1.1 [n = 9] vs. CGC/XXX = 2.5 ± 1.7 [n = 36] vs. XXX/XXX = 2.7 ± 1.7 ng/mL per mg/d [n = 20]; p = 0.9).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],2.7,143178,DB00877,Sirolimus
,24628014,L/D,EVR L/D was 3.4 ± 1.7 in LTxR receiving diltiazem (DILT) vs. 1.8 ± 1.1 ng/mL per mg/d in LTxR not receiving DILT (p <0.001).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],3.4,143179,DB00877,Sirolimus
,24628014,L/D,EVR L/D was 3.4 ± 1.7 in LTxR receiving diltiazem (DILT) vs. 1.8 ± 1.1 ng/mL per mg/d in LTxR not receiving DILT (p <0.001).,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628014/),[ng] / [d·mg·ml],1.8,143180,DB00877,Sirolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],40.50,144481,DB00877,Sirolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.08,144482,DB00877,Sirolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],43.00,144483,DB00877,Sirolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.85,144484,DB00877,Sirolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],56.75,144485,DB00877,Sirolimus
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],36.20,144486,DB00877,Sirolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.83,144487,DB00877,Sirolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],12.08,144488,DB00877,Sirolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.77,144489,DB00877,Sirolimus
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],13.00,144490,DB00877,Sirolimus
,21913034,C (max),PK analysis of everolimus demonstrated dose-proportional increases in C (max) (mean 91.9 ng/ml) and AUC(0-INF) (mean 680.5 h*ng/ml) at dose level 4.,A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913034/),[ng] / [ml],91.9,145668,DB00877,Sirolimus
,21913034,AUC(0-INF),PK analysis of everolimus demonstrated dose-proportional increases in C (max) (mean 91.9 ng/ml) and AUC(0-INF) (mean 680.5 h*ng/ml) at dose level 4.,A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913034/),[h·ng] / [ml],680.5,145669,DB00877,Sirolimus
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],5.2,149623,DB00877,Sirolimus
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],9.4,149624,DB00877,Sirolimus
<,14550821,trough levels,"We observed a significantly increased risk of acute rejection at everolimus trough levels <3 ng/ml, which constitutes the lower therapeutic concentration limit when everolimus is used with conventionally dosed cyclosporine.","Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],3,149625,DB00877,Sirolimus
,14550821,troughs,Everolimus-related adverse events were manageable up to the highest troughs (22 ng/ml) observed in this population.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],22,149626,DB00877,Sirolimus
,15785960,C (max),"During erythromycin coadministration, everolimus C (max) increased 2.0-fold (90% CI, 1.8-2.3) from 20+/-5 ng/ml to 40+/-10 ng/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[ng] / [ml],20,149749,DB00877,Sirolimus
,15785960,C (max),"During erythromycin coadministration, everolimus C (max) increased 2.0-fold (90% CI, 1.8-2.3) from 20+/-5 ng/ml to 40+/-10 ng/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[ng] / [ml],40,149750,DB00877,Sirolimus
,15785960,AUC,"Everolimus AUC increased 4.4-fold (90% CI, 3.5-5.4) from 116+/-37 ng h/ml to 524+/-225 ng h/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[h·ng] / [ml],116,149751,DB00877,Sirolimus
,15785960,AUC,"Everolimus AUC increased 4.4-fold (90% CI, 3.5-5.4) from 116+/-37 ng h/ml to 524+/-225 ng h/ml.",Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),[h·ng] / [ml],524,149752,DB00877,Sirolimus
,15785960,half-life,Everolimus half-life was prolonged by 39% from 32+/-6 h to 44+/-6 h.,Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),h,32,149753,DB00877,Sirolimus
,15785960,half-life,Everolimus half-life was prolonged by 39% from 32+/-6 h to 44+/-6 h.,Effect of multiple-dose erythromycin on everolimus pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15785960/),h,44,149754,DB00877,Sirolimus
,9840435,m/z,"Detection was by multiple reactant monitoring with the mass transitions m/z 931.8-->864.6 and m/z 901.8-->834.4 employed for sirolimus and the internal standard, respectively.",Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840435/),,931.8,151000,DB00877,Sirolimus
,9840435,m/z,"Detection was by multiple reactant monitoring with the mass transitions m/z 931.8-->864.6 and m/z 901.8-->834.4 employed for sirolimus and the internal standard, respectively.",Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840435/),,864.6,151001,DB00877,Sirolimus
,9840435,m/z,"Detection was by multiple reactant monitoring with the mass transitions m/z 931.8-->864.6 and m/z 901.8-->834.4 employed for sirolimus and the internal standard, respectively.",Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840435/),,901.8,151002,DB00877,Sirolimus
,9840435,m/z,"Detection was by multiple reactant monitoring with the mass transitions m/z 931.8-->864.6 and m/z 901.8-->834.4 employed for sirolimus and the internal standard, respectively.",Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840435/),,834.4,151003,DB00877,Sirolimus
,9840435,absolute recovery,"The mean absolute recovery of sirolimus and the internal standard were 80.5% and 81.3%, respectively.",Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840435/),%,80.5,151004,DB00877,Sirolimus
,9840435,absolute recovery,"The mean absolute recovery of sirolimus and the internal standard were 80.5% and 81.3%, respectively.",Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840435/),%,81.3,151005,DB00877,Sirolimus
,30415142,m/z,The highest response ion pairs m/z at 931.5→864.5 were chosen for sirolimus.,Pharmacokinetic study of sirolimus ophthalmic formulations by consecutive sampling and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30415142/),,931.5,151249,DB00877,Sirolimus
,30415142,m/z,The highest response ion pairs m/z at 931.5→864.5 were chosen for sirolimus.,Pharmacokinetic study of sirolimus ophthalmic formulations by consecutive sampling and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30415142/),,864.5,151250,DB00877,Sirolimus
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],62.1-67.8,151954,DB00877,Sirolimus
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],33.6-64.7,151955,DB00877,Sirolimus
,16027400,total trough concentrations,Median total trough concentrations were 1.16-2.90 mcg/mL.,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[mcg] / [ml],1.16-2.90,151956,DB00877,Sirolimus
,16027400,Unbound AUC(0-12),Unbound AUC(0-12) was 412-673 ng x h/mL and did not change over time (P = .30).,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·ng] / [ml],412-673,151957,DB00877,Sirolimus
,10594471,elimination half-life,The elimination half-life ranged from 24 to 35 h across the five highest dose groups.,Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594471/),h,24 to 35,153257,DB00877,Sirolimus
,18926156,T(max),"Across all dose levels, individual T(max) values ranged from 0.13 and 2.17 hours; individual C(max) ranged from 0.14 to 2.79 ng/mL.",Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18926156/),h,0.13,154519,DB00877,Sirolimus
,18926156,T(max),"Across all dose levels, individual T(max) values ranged from 0.13 and 2.17 hours; individual C(max) ranged from 0.14 to 2.79 ng/mL.",Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18926156/),h,2.17,154520,DB00877,Sirolimus
,18926156,C(max),"Across all dose levels, individual T(max) values ranged from 0.13 and 2.17 hours; individual C(max) ranged from 0.14 to 2.79 ng/mL.",Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18926156/),[ng] / [ml],0.14 to 2.79,154521,DB00877,Sirolimus
,18812562,steady-state minimum concentration (C(min)),Satisfactory steady-state minimum concentration (C(min)) of everolimus was achieved (approximately 5 ng/mL).,Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],5,154970,DB00877,Sirolimus
,18812562,C(min),"At that time, the everolimus C(min) averaged approximately 3 ng/mL.",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],3,154971,DB00877,Sirolimus
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154972,DB00877,Sirolimus
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154973,DB00877,Sirolimus
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154974,DB00877,Sirolimus
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154975,DB00877,Sirolimus
,32720540,apparent clearance (CL/F),"The outcome parameters were as follows: apparent clearance (CL/F) 5.63 L/h, apparent distribution volume (V/F) 144.16 L.",The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32720540/),[l] / [h],5.63,157163,DB00877,Sirolimus
,32720540,apparent distribution volume (V/F),"The outcome parameters were as follows: apparent clearance (CL/F) 5.63 L/h, apparent distribution volume (V/F) 144.16 L.",The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32720540/),l,144.16,157164,DB00877,Sirolimus
,11571449,half-life,"Pharmacokinetic analysis in the first week of SRL administration suggested a short half-life (11.8+/-5.5 hr, n=21).",Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571449/),h,11.8,158457,DB00877,Sirolimus
,9156373,time to peak blood concentration,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),h,1.4,159990,DB00877,Sirolimus
,9156373,terminal half-life,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),h,62,159991,DB00877,Sirolimus
,9156373,oral dose clearance,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),[ml] / [h·kg],208,159992,DB00877,Sirolimus
,9156373,apparent oral steady-state volume of distribution,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),[l] / [kg],12,159993,DB00877,Sirolimus
,9156373,blood/plasma ratio,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),,38,159994,DB00877,Sirolimus
,9263380,blood/ plasma ratio,Blood and plasma sirolimus concentrations were analyzed by an electrospray-high performance liquid/mass spectrophotometric (ESP-HPLC/MS) method Sirolimus showed an extensive red blood cell distribution with a mean blood/ plasma ratio of 49.1.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),,49.1,160379,DB00877,Sirolimus
,9263380,elimination half-life,The elimination half-life ranged from 43.8 to 86.5 hours (mean 56.9 hours).,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),h,56.9,160380,DB00877,Sirolimus
,9263380,oral dose clearance,The oral dose clearance ranged from 42 to 339 ml/h.kg.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),[ml] / [h·kg],42 to 339,160381,DB00877,Sirolimus
,24655978,AUC0-12,"The mean (SD) AUC0-12 for EVL and EVL plus atorvastatin was 155.9 (41.6) ng·h/mL and 151.3 (51.4) ng·h/mL, respectively (P > .05; paired t test).",Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655978/),[h·ng] / [ml],155.9,160864,DB00877,Sirolimus
,24655978,AUC0-12,"The mean (SD) AUC0-12 for EVL and EVL plus atorvastatin was 155.9 (41.6) ng·h/mL and 151.3 (51.4) ng·h/mL, respectively (P > .05; paired t test).",Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655978/),[h·ng] / [ml],151.3,160865,DB00877,Sirolimus
,24923538,platelet nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,0 × 10(9),162089,DB00877,Sirolimus
,24923538,leukocyte nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,1.0 × 10(9),162090,DB00877,Sirolimus
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [l],19.1,162091,DB00877,Sirolimus
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[mg] / [l],.3,162092,DB00877,Sirolimus
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [h·l],325,162093,DB00877,Sirolimus
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[ng] / [h·l],29.6,162094,DB00877,Sirolimus
,22143911,maximum concentration (C(max)),"Mean maximum concentration (C(max)), time to C(max) (t(max)), area under the curve for the given dose interval (AUC(tau)), and whole blood oral clearance at 3 months were 20.8 ± 7.6 ng/mL, 3 ± 1 h, 338 ± 144 ng·h/mL, and 10.0 ± 5.6 L/hr, respectively.",Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143911/),[ng] / [ml],20.8,162347,DB00877,Sirolimus
,22143911,time to C(max) (t(max)),"Mean maximum concentration (C(max)), time to C(max) (t(max)), area under the curve for the given dose interval (AUC(tau)), and whole blood oral clearance at 3 months were 20.8 ± 7.6 ng/mL, 3 ± 1 h, 338 ± 144 ng·h/mL, and 10.0 ± 5.6 L/hr, respectively.",Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143911/),h,3,162348,DB00877,Sirolimus
,22143911,time to C(max) (t(max)),"Mean maximum concentration (C(max)), time to C(max) (t(max)), area under the curve for the given dose interval (AUC(tau)), and whole blood oral clearance at 3 months were 20.8 ± 7.6 ng/mL, 3 ± 1 h, 338 ± 144 ng·h/mL, and 10.0 ± 5.6 L/hr, respectively.",Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143911/),[h·ng] / [ml],338,162349,DB00877,Sirolimus
,22143911,area under the curve for the given dose interval (AUC(tau)),"Mean maximum concentration (C(max)), time to C(max) (t(max)), area under the curve for the given dose interval (AUC(tau)), and whole blood oral clearance at 3 months were 20.8 ± 7.6 ng/mL, 3 ± 1 h, 338 ± 144 ng·h/mL, and 10.0 ± 5.6 L/hr, respectively.",Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143911/),h,3,162350,DB00877,Sirolimus
,22143911,area under the curve for the given dose interval (AUC(tau)),"Mean maximum concentration (C(max)), time to C(max) (t(max)), area under the curve for the given dose interval (AUC(tau)), and whole blood oral clearance at 3 months were 20.8 ± 7.6 ng/mL, 3 ± 1 h, 338 ± 144 ng·h/mL, and 10.0 ± 5.6 L/hr, respectively.",Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143911/),[h·ng] / [ml],338,162351,DB00877,Sirolimus
,22143911,whole blood oral clearance,"Mean maximum concentration (C(max)), time to C(max) (t(max)), area under the curve for the given dose interval (AUC(tau)), and whole blood oral clearance at 3 months were 20.8 ± 7.6 ng/mL, 3 ± 1 h, 338 ± 144 ng·h/mL, and 10.0 ± 5.6 L/hr, respectively.",Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143911/),[l] / [h],10.0,162352,DB00877,Sirolimus
,23884207,bioavailability,With the well stirred and Qgut models sirolimus bioavailability was predicted at 15%.,Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884207/),%,15,165283,DB00877,Sirolimus
,31089971,AUCinf,"Mean AUCinf at the 40 mg dose in the fasted state was 4,300 ± 1,083 ng·h/ml, which is 28% higher than the AUC reported following the administration of 90 (2 × 45) mg Rapamune® and 11% higher than the exposure reported for 25 mg intravenous pro-drug temsirolimus (3,810 ng·h/ml).",Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089971/),[h·ng] / [ml],"4,300",165393,DB00877,Sirolimus
,31089971,AUCinf,"Mean AUCinf at the 40 mg dose in the fasted state was 4,300 ± 1,083 ng·h/ml, which is 28% higher than the AUC reported following the administration of 90 (2 × 45) mg Rapamune® and 11% higher than the exposure reported for 25 mg intravenous pro-drug temsirolimus (3,810 ng·h/ml).",Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089971/),[h·ng] / [ml],"3,810",165394,DB00877,Sirolimus
,31095909,bioavailability,"A complete pharmacokinetic (PK) analysis of FAF revealed that the bioavailability of SC FAF was 60%, with significantly higher blood concentration during the elimination phase compared to IV FAF.",Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31095909/),%,60,166573,DB00877,Sirolimus
,20484171,trough concentration,Sirolimus concentrations obtained 3 days after initiation of dronedarone revealed a trough concentration that was increased by more than 3-fold (38.6 ng/mL) from his baseline trough concentration.,Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],38.6,168424,DB00877,Sirolimus
,20484171,trough concentration,"After sirolimus was held for 6 days, the trough concentration was 7.8 ng/mL.",Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],7.8,168425,DB00877,Sirolimus
,18641543,AUC,"The mean MPA AUC as well as the standard deviation was much greater in the SRL group, 56.4 +/- 23.5 mg.h/L, compared with 30.4 +/- 11.0 mg.h/L in the cyclosporine group (P < 0.001).",Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[h·mg] / [l],56.4,172406,DB00877,Sirolimus
,18641543,AUC,"The mean MPA AUC as well as the standard deviation was much greater in the SRL group, 56.4 +/- 23.5 mg.h/L, compared with 30.4 +/- 11.0 mg.h/L in the cyclosporine group (P < 0.001).",Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[h·mg] / [l],30.4,172407,DB00877,Sirolimus
,18641543,maximum concentration,Mean maximum concentration was also greater in the SRL group: 16.4 +/- 7.7 mg/L versus 11.7 +/- 7.1mg/L (P < 0.005).,Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[mg] / [l],16.4,172408,DB00877,Sirolimus
,18641543,maximum concentration,Mean maximum concentration was also greater in the SRL group: 16.4 +/- 7.7 mg/L versus 11.7 +/- 7.1mg/L (P < 0.005).,Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[mg] / [l],11.7,172409,DB00877,Sirolimus
,22844126,Objective response rate,"Objective response rate was 11% (95% confidence interval: 5, 20), median progression-free survival was 7.3 months (95% confidence interval: 4.0, 9.2) and median time to treatment failure was 5.4 months (95% confidence interval: 3.5, 7.4).",Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22844126/),%,11,172522,DB00877,Sirolimus
,22844126,progression-free survival,"Objective response rate was 11% (95% confidence interval: 5, 20), median progression-free survival was 7.3 months (95% confidence interval: 4.0, 9.2) and median time to treatment failure was 5.4 months (95% confidence interval: 3.5, 7.4).",Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22844126/),month,7.3,172523,DB00877,Sirolimus
,22844126,time to treatment failure,"Objective response rate was 11% (95% confidence interval: 5, 20), median progression-free survival was 7.3 months (95% confidence interval: 4.0, 9.2) and median time to treatment failure was 5.4 months (95% confidence interval: 3.5, 7.4).",Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22844126/),month,5.4,172524,DB00877,Sirolimus
,24122637,C max,The C max was 85.3 ± 37.9 pg/mL (min-max 46.7-169 pg/mL) in the 18 mm cohort and 198 ± 81 pg/mL (min-max 82.5-365 pg/mL) in the ≥ 28 mm cohort and no early or late bursts of biolimus A9 release were documented.,Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122637/),[pg] / [ml],85.3,173023,DB00877,Sirolimus
,24122637,C max,The C max was 85.3 ± 37.9 pg/mL (min-max 46.7-169 pg/mL) in the 18 mm cohort and 198 ± 81 pg/mL (min-max 82.5-365 pg/mL) in the ≥ 28 mm cohort and no early or late bursts of biolimus A9 release were documented.,Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122637/),[pg] / [ml],198,173024,DB00877,Sirolimus
,24122637,AUC0-t,"Estimated AUC0-t was 1.12 ± 1.16 ng/mL h in the 18 mm group, and 5.93 ± 4.41 ng/mL h for the ≥ 28 mm group.",Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122637/),[ng] / [h·ml],1.12,173025,DB00877,Sirolimus
,24122637,AUC0-t,"Estimated AUC0-t was 1.12 ± 1.16 ng/mL h in the 18 mm group, and 5.93 ± 4.41 ng/mL h for the ≥ 28 mm group.",Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122637/),[ng] / [h·ml],5.93,173026,DB00877,Sirolimus
,16027401,CL,"The mean CL, V(ss), and t(1/2) ranges were 4.0 to 4.6 L/h, 92.5 to 118.0 L, and 24.7 to 31.0 hours, respectively.",A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027401/),[l] / [h],4.0 to 4.6,175084,DB00877,Sirolimus
,16027401,V(ss),"The mean CL, V(ss), and t(1/2) ranges were 4.0 to 4.6 L/h, 92.5 to 118.0 L, and 24.7 to 31.0 hours, respectively.",A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027401/),l,92.5 to 118.0,175085,DB00877,Sirolimus
,16027401,t(1/2),"The mean CL, V(ss), and t(1/2) ranges were 4.0 to 4.6 L/h, 92.5 to 118.0 L, and 24.7 to 31.0 hours, respectively.",A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027401/),h,24.7 to 31.0,175086,DB00877,Sirolimus
,26990259,trough concentration,To examine whether a trough concentration of everolimus in the therapeutic range of 3-5 ng/mL affects the pharmacokinetics of tacrolimus in renal transplant patients.,Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26990259/),[ng] / [ml],3-5,175895,DB00877,Sirolimus
,18757332,MTD,The MTD of daily oral rapamycin was 6 mg.,"Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757332/),mg,6,176259,DB00877,Sirolimus
,25359003,T1/2,"Pharmacokinetic analysis revealed that Tregs have two phases of elimination: an α phase, with a T1/2 in the peripheral blood of 32.4 ± 11.3 h and a β phase with a T1/2 of 120.4 ± 19.7 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,32.4,178109,DB00877,Sirolimus
,25359003,T1/2,"Pharmacokinetic analysis revealed that Tregs have two phases of elimination: an α phase, with a T1/2 in the peripheral blood of 32.4 ± 11.3 h and a β phase with a T1/2 of 120.4 ± 19.7 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,120.4,178110,DB00877,Sirolimus
,25359003,α phase,"In contrast, rapamycin significantly stabilized both CD25 and FoxP3, and supported an increased half-life, with an α phase of 67.7 ± 6.9 h and a β phase of 252.1 ± 54.9 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,67.7,178111,DB00877,Sirolimus
,25359003,β phase,"In contrast, rapamycin significantly stabilized both CD25 and FoxP3, and supported an increased half-life, with an α phase of 67.7 ± 6.9 h and a β phase of 252.1 ± 54.9 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,252.1,178112,DB00877,Sirolimus
,31863795,neointima area,"Arteries treated with Nanolimus showed significant reduction in neointima area (0.2 ± 0.3 mm2 vs 2.0 ± 1.2 mm2, p < 0.01) and luminal stenosis (14.2 ± 7.2% vs. 67.7 ± 24.8%, p < 0.01) compared to controls.",Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31863795/),mm2,0.2,178254,DB00877,Sirolimus
,31863795,neointima area,"Arteries treated with Nanolimus showed significant reduction in neointima area (0.2 ± 0.3 mm2 vs 2.0 ± 1.2 mm2, p < 0.01) and luminal stenosis (14.2 ± 7.2% vs. 67.7 ± 24.8%, p < 0.01) compared to controls.",Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31863795/),mm2,2.0,178255,DB00877,Sirolimus
,21299636,AUC(12h),Only six of 24 patients had an MPA-AUC(12h) within the putative therapeutic range of 40-60 mg/L·h.,Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299636/),[mg] / [h·l],40-60,180132,DB00877,Sirolimus
> or =,20517177,target trough levels,"Data were from a prospective, multicenter, open-label, randomized, exploratory 6-month study of 92 renal transplant patients treated de novo with concentration-controlled Evl (target trough levels > or =3 ng/mL) plus low-dose Tac or Evl plus standard-dose Tac; both groups received basiliximab and corticosteroids.",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180909,DB00877,Sirolimus
less,20517177,Evl,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180910,DB00877,Sirolimus
less,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180911,DB00877,Sirolimus
less,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3 to 8,180912,DB00877,Sirolimus
more,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],8,180913,DB00877,Sirolimus
more,20517177,Evl trough level,Evl trough level of more than or equal to 3 ng/mL was associated with significantly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180914,DB00877,Sirolimus
less,20517177,trough level,Evl trough level of more than or equal to 3 ng/mL was associated with significantly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180915,DB00877,Sirolimus
> or =,20517177,trough levels,Evl trough levels > or =3 ng/mL plus Tac are associated with low rates of BPAR without adversely affecting renal function.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180916,DB00877,Sirolimus
,24859653,systemic circulation (AUC₀₋₂₄),"Despite higher pulmonary levels of drug that were found for the crystalline group, the systemic circulation (AUC₀₋₂₄) was higher for the amorphous group (8.6 ngh/mL) than for crystalline group (2.4 ngh/mL) based on a five-compartmental analysis.",Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24859653/),[ngh] / [ml],8.6,181063,DB00877,Sirolimus
,24859653,systemic circulation (AUC₀₋₂₄),"Despite higher pulmonary levels of drug that were found for the crystalline group, the systemic circulation (AUC₀₋₂₄) was higher for the amorphous group (8.6 ngh/mL) than for crystalline group (2.4 ngh/mL) based on a five-compartmental analysis.",Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24859653/),[ngh] / [ml],2.4,181064,DB00877,Sirolimus
,9892474,terminal half-life,Pred terminal half-life and clearance were 1.1 hr and 0.72 l/hr/kg with no difference after Sir.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),h,1.1,181881,DB00877,Sirolimus
,9892474,clearance,Pred terminal half-life and clearance were 1.1 hr and 0.72 l/hr/kg with no difference after Sir.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),[l] / [h·kg],0.72,181882,DB00877,Sirolimus
,9892474,Sir,Sir values were 13 hr and 0.16 l/hr/kg and Pred produced no changes.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),h,13,181883,DB00877,Sirolimus
,9892474,Sir,Sir values were 13 hr and 0.16 l/hr/kg and Pred produced no changes.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),[l] / [h·kg],0.16,181884,DB00877,Sirolimus
,20003043,survival,"In the DA to LEW model, combining a nonefficacious dose of AEB (10 mg/kg b.i.d.) with a nonefficacious dose of cyclosporine, everolimus or FTY720 led to prolonged median survival times (26 days, >68 days and >68 days, respectively).","Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003043/),d,26,182384,DB00877,Sirolimus
>,20003043,survival,"In the DA to LEW model, combining a nonefficacious dose of AEB (10 mg/kg b.i.d.) with a nonefficacious dose of cyclosporine, everolimus or FTY720 led to prolonged median survival times (26 days, >68 days and >68 days, respectively).","Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003043/),d,68,182385,DB00877,Sirolimus
,25940522,Peak sirolimus concentrations,"Peak sirolimus concentrations were 13.6 ± 4.5 μg/L (24.8 μg/L highest) and clearance was 0.042 ± 0.03 L/hour (noncompartmental analysis) and 0.051 L/hour (95% credible intervals 0.037-0.069, nonlinear mixed model).",Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial duct. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25940522/),[μg] / [l],13.6,184721,DB00877,Sirolimus
,25940522,Peak sirolimus concentrations,"Peak sirolimus concentrations were 13.6 ± 4.5 μg/L (24.8 μg/L highest) and clearance was 0.042 ± 0.03 L/hour (noncompartmental analysis) and 0.051 L/hour (95% credible intervals 0.037-0.069, nonlinear mixed model).",Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial duct. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25940522/),[μg] / [l],24.8,184722,DB00877,Sirolimus
,25940522,clearance,"Peak sirolimus concentrations were 13.6 ± 4.5 μg/L (24.8 μg/L highest) and clearance was 0.042 ± 0.03 L/hour (noncompartmental analysis) and 0.051 L/hour (95% credible intervals 0.037-0.069, nonlinear mixed model).",Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial duct. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25940522/),[l] / [h],0.042,184723,DB00877,Sirolimus
,25940522,clearance,"Peak sirolimus concentrations were 13.6 ± 4.5 μg/L (24.8 μg/L highest) and clearance was 0.042 ± 0.03 L/hour (noncompartmental analysis) and 0.051 L/hour (95% credible intervals 0.037-0.069, nonlinear mixed model).",Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial duct. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25940522/),[l] / [h],0.051,184724,DB00877,Sirolimus
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],44.9,185175,DB00877,Sirolimus
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],30.5,185176,DB00877,Sirolimus
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,4.3,188010,DB00877,Sirolimus
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,3.6,188011,DB00877,Sirolimus
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,1.9,188012,DB00877,Sirolimus
,15518745,dose-normalized C(0),The mean dose-normalized C(0) was 2.13 +/- 0.91 ng/mL/mg.,Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518745/),[ng] / [mg·ml],2.13,188527,DB00877,Sirolimus
,15498365,Peak whole blood concentration (Cmax),"Peak whole blood concentration (Cmax), time to peak concentration (tmax), elimination half-life (t1/2beta), area under the curve (AUC), and apparent systemic clearance (Cl/F) were (10.91 +/- 1.28) ng/ml, (2.0 +/- 0.2) hours, (7.25 +/- 0.63) hours, (1.15 +/- 0.11) ng x h x ml(-1), and (180 +/- 12) ml x h(-1) x kg(-1), respectively.",Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498365/),[ng] / [ml],10.91,189133,DB00877,Sirolimus
,15498365,apparent systemic clearance (Cl/F),"Peak whole blood concentration (Cmax), time to peak concentration (tmax), elimination half-life (t1/2beta), area under the curve (AUC), and apparent systemic clearance (Cl/F) were (10.91 +/- 1.28) ng/ml, (2.0 +/- 0.2) hours, (7.25 +/- 0.63) hours, (1.15 +/- 0.11) ng x h x ml(-1), and (180 +/- 12) ml x h(-1) x kg(-1), respectively.",Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498365/),[ml] / [h·kg],180,189134,DB00877,Sirolimus
,14990647,objective response rate,CCI-779 produced an objective response rate of 7% (one complete response and seven partial responses) and minor responses in 26% of these advanced RCC patients.,"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990647/),%,7,190852,DB00877,Sirolimus
,14990647,time to tumor progression,Median time to tumor progression was 5.8 months and median survival was 15.0 months.,"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990647/),month,5.8,190853,DB00877,Sirolimus
,14990647,survival,Median time to tumor progression was 5.8 months and median survival was 15.0 months.,"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990647/),month,15.0,190854,DB00877,Sirolimus
,11510015,trough levels,"A series of 56 liver transplant recipients were administered a combination of SRL and TAC (target trough levels, 7 and 5 ng/mL, respectively).",Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510015/),[ng] / [ml],7,191276,DB00877,Sirolimus
,11510015,trough levels,"A series of 56 liver transplant recipients were administered a combination of SRL and TAC (target trough levels, 7 and 5 ng/mL, respectively).",Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510015/),[ng] / [ml],5,191277,DB00877,Sirolimus
,11510015,rate of acute cellular rejection,The rate of acute cellular rejection was 14%.,Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510015/),%,14,191278,DB00877,Sirolimus
,21825263,MTD,"The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting.",Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21825263/),mg,25,191723,DB00877,Sirolimus
,16623021,time to maximal concentration (Tmax),The mean (+/- SD) time to maximal concentration (Tmax) was 1.45 +/- 0.5 hr (range 1-3 hrs).,Pharmacokinetics of sirolimus in Thai healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16623021/),h,1.45,192672,DB00877,Sirolimus
,16623021,maximal (Cm),The maximal (Cm) and minimal plasma concentration (Ctroug) for sirolimus were 25.3 +/- 6.1 ng/ml (range 18.10 - 40 ng/ml) and 4.47 +/- 0.57 ng/ml (range 2.90 - 7.20) ng/ml respectively.,Pharmacokinetics of sirolimus in Thai healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16623021/),[ng] / [ml],25.3,192673,DB00877,Sirolimus
,16623021,minimal plasma concentration (Ctroug),The maximal (Cm) and minimal plasma concentration (Ctroug) for sirolimus were 25.3 +/- 6.1 ng/ml (range 18.10 - 40 ng/ml) and 4.47 +/- 0.57 ng/ml (range 2.90 - 7.20) ng/ml respectively.,Pharmacokinetics of sirolimus in Thai healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16623021/),[ng] / [ml],4.47,192674,DB00877,Sirolimus
,16623021,AUC(0-24 hr),The AUC(0-24 hr) were 187.9 +/- 48.2 ng * hr/ml (range 151.3 - 294.8 ng * hr/ml).,Pharmacokinetics of sirolimus in Thai healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16623021/),[h·ng] / [ml],187.9,192675,DB00877,Sirolimus
,16623021,AUC(0-24 hr),This subject's pharmacokinetic data showed AUC(0-24 hr) of 256 ng * hr/ml and Cmax of 40 ng/ml.,Pharmacokinetics of sirolimus in Thai healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16623021/),[h·ng] / [ml],256,192676,DB00877,Sirolimus
,16623021,Cmax,This subject's pharmacokinetic data showed AUC(0-24 hr) of 256 ng * hr/ml and Cmax of 40 ng/ml.,Pharmacokinetics of sirolimus in Thai healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16623021/),[ng] / [ml],40,192677,DB00877,Sirolimus
,17164687,tmax,Sirolimus also had a significant effect on the FPIA/LC-MS ratio at 12 hour in studies with tmax at 2 hours (P = 0.042) but not 4 hours (P = 0.735).,12-hour area under the curve cyclosporine concentrations determined by a validated liquid chromatography-mass spectrometry procedure compared with fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164687/),h,2,193007,DB00877,Sirolimus
,17164687,tmax,Sirolimus also had a significant effect on the FPIA/LC-MS ratio at 12 hour in studies with tmax at 2 hours (P = 0.042) but not 4 hours (P = 0.735).,12-hour area under the curve cyclosporine concentrations determined by a validated liquid chromatography-mass spectrometry procedure compared with fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164687/),h,4,193008,DB00877,Sirolimus
,19660003,apparent clearance (CL/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 10.1 l h(-1) (23.8%) and 3670 l (56.7%), respectively.",Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660003/),[l] / [h],10.1,194447,DB00877,Sirolimus
,19660003,apparent volume of distribution (V/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 10.1 l h(-1) (23.8%) and 3670 l (56.7%), respectively.",Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660003/),l,3670,194448,DB00877,Sirolimus
more,23328074,maximum tolerated dose (MTD),A pediatric study has established a maximum tolerated dose (MTD) for temsirolimus (Tem) of more than 150 mg/m intravenously/week.,Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328074/),[mg] / [m],150,194972,DB00877,Sirolimus
,27798513,trough level (Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],3-8,195366,DB00877,Sirolimus
,27798513,Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],2-5,195367,DB00877,Sirolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],7.2,195368,DB00877,Sirolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.9,195369,DB00877,Sirolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.5,195370,DB00877,Sirolimus
,27798513,Ctrough,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.7,195371,DB00877,Sirolimus
,27798513,AUC0-12h,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [h·ml],106,195372,DB00877,Sirolimus
,27798513,Caverage,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],8.8,195373,DB00877,Sirolimus
,27798513,Cmax,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],19.2,195374,DB00877,Sirolimus
,27798513,apparent Half-life,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),h,11.7,195375,DB00877,Sirolimus
,27798513,total body clearance,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[l] / [h],0.39,195376,DB00877,Sirolimus
,23913602,inflammation score,"At 28 days, inflammation was significantly less in the EES group as compared to the R-ZES group (inflammation score: 1.59 ± 0.52 vs 2.22 ± 0.69, respectively; P=.044), with no differences observed at 60 days.",Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23913602/),,1.59,195520,DB00877,Sirolimus
,23913602,inflammation score,"At 28 days, inflammation was significantly less in the EES group as compared to the R-ZES group (inflammation score: 1.59 ± 0.52 vs 2.22 ± 0.69, respectively; P=.044), with no differences observed at 60 days.",Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23913602/),,2.22,195521,DB00877,Sirolimus
<,20963405,A9 concentrations,"At 28 days and 6 months following stent placement, 51.8 and 100% of patients, respectively, had Biolimus A9 concentrations <10 pg/mL.",The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20963405/),p,10,195888,DB00877,Sirolimus
,23829943,absorption lag-time,"The median absorption lag-time was 2 hours, the median Tmax was 4 hours and the mean elimination half-life was 53 hours.",A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829943/),h,2,195999,DB00877,Sirolimus
,23829943,Tmax,"The median absorption lag-time was 2 hours, the median Tmax was 4 hours and the mean elimination half-life was 53 hours.",A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829943/),h,4,196000,DB00877,Sirolimus
,23829943,elimination half-life,"The median absorption lag-time was 2 hours, the median Tmax was 4 hours and the mean elimination half-life was 53 hours.",A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829943/),h,53,196001,DB00877,Sirolimus
,23829943,accumulation ratio for AUC(0-24hr),The accumulation ratio for AUC(0-24hr) was 1.3 on day 19 (steady state)/day 1 (after a single dose).,A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23829943/),,1.3,196002,DB00877,Sirolimus
,27713169,RP2D,The RP2D for oral ridaforolimus in children was defined as 33 mg/m2.,A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27713169/),[mg] / [m2],33,196488,DB00877,Sirolimus
,22051872,maximum observed everolimus blood concentrations (C(max)),"Following the procedure, the maximum observed everolimus blood concentrations (C(max)) varied from 1.83 ± 0.05 ng/mL after implantation of a single 80-mm stent to 4.66 ± 1.78 ng/mL after implantation of two 100-mm stents.",Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),[ng] / [ml],1.83,197445,DB00877,Sirolimus
,22051872,maximum observed everolimus blood concentrations (C(max)),"Following the procedure, the maximum observed everolimus blood concentrations (C(max)) varied from 1.83 ± 0.05 ng/mL after implantation of a single 80-mm stent to 4.66 ± 1.78 ng/mL after implantation of two 100-mm stents.",Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),[ng] / [ml],4.66,197446,DB00877,Sirolimus
,22051872,time to peak concentration (T(max)),The mean time to peak concentration (T(max)) varied from 6.8 hours to 35 hours.,Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),h,6.8,197447,DB00877,Sirolimus
,22051872,time to peak concentration (T(max)),The mean time to peak concentration (T(max)) varied from 6.8 hours to 35 hours.,Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22051872/),h,35,197448,DB00877,Sirolimus
,18842108,Analytical time,Analytical time was 4 min/injection.,A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18842108/),[min] / [injection],4,197577,DB00877,Sirolimus
,18842108,carryover,No carryover was detected from samples at 313.6 ng/mL.,A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18842108/),ng,313.,197578,DB00877,Sirolimus
,16342216,peak concentration,"Non-compartmental analysis showed that the maximum blood concentration of sirolimus occurred between 3 and 4 hr after implantation, with a peak concentration of 0.57 +/- 0.12 ng/mL (mean +/- SD) and 1.05 +/- 0.39 ng/mL in patients receiving one or two stents, respectively.",Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342216/),[ng] / [ml],0.57,198996,DB00877,Sirolimus
,16342216,peak concentration,"Non-compartmental analysis showed that the maximum blood concentration of sirolimus occurred between 3 and 4 hr after implantation, with a peak concentration of 0.57 +/- 0.12 ng/mL (mean +/- SD) and 1.05 +/- 0.39 ng/mL in patients receiving one or two stents, respectively.",Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342216/),[ng] / [ml],1.05,198997,DB00877,Sirolimus
,16342216,Terminal-phase elimination half-life,"Terminal-phase elimination half-life was independent of the number of stents and averaged at 213 hr, a value longer than that seen in patients following oral dosing.",Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342216/),h,213,198998,DB00877,Sirolimus
,16342216,apparent clearance,The apparent clearance was 1.46 +/- 0.45 L/hr with an apparent volume of distribution in the terminal phase of 407 +/- 111 L (data for both stent doses pooled).,Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342216/),[l] / [h],1.46,198999,DB00877,Sirolimus
,16342216,apparent volume of distribution in the terminal phase,The apparent clearance was 1.46 +/- 0.45 L/hr with an apparent volume of distribution in the terminal phase of 407 +/- 111 L (data for both stent doses pooled).,Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16342216/),l,407,199000,DB00877,Sirolimus
,20972652,overall response rate,Two patients with diffuse large B cell lymphoma and two patients with follicular lymphomas achieved objective responses with an overall response rate of 31% (4/13).,Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20972652/),%,31,199202,DB00877,Sirolimus
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],80.3,199420,DB00877,Sirolimus
,24521776,AUC0-12,"Everolimus AUC0-12 was not affected by concomitant rosuvastatin treatment, 80.3±21.3 μg*h/L before and 78.5±21.9 μg*h/L after, respectively (P=0.61).",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·μg] / [l],78.5,199421,DB00877,Sirolimus
,24521776,AUC0-24,"Mean rosuvastatin AUC0-24 was 157±61.7 ng*h/mL, approximately threefold higher than reported in the literature for nontransplants.",More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521776/),[h·ng] / [ml],157,199422,DB00877,Sirolimus
,20335831,Cmin,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),[ng] / [ml],11.1,200282,DB00877,Sirolimus
,20335831,Cmin,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),[ng] / [ml],9.4,200283,DB00877,Sirolimus
,20335831,area under the curves,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),,162,200284,DB00877,Sirolimus
,20335831,area under the curves,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),,171,200285,DB00877,Sirolimus
,19709321,peak,"In the following days, an increase in tacrolimus concentration was observed with a peak of 37 ng/mL.",Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),[ng] / [ml],37,200411,DB00877,Sirolimus
,19709321,half-life,Tacrolimus half-life was 6.5 days and tacrolimus maintenance dose was 0.5 mg every 4 days.,Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),d,6.5,200412,DB00877,Sirolimus
,33277457,maintenance trough level,The usual maintenance dose of Sirolimus in these patients is 2 to 5 mg/d and its optimal maintenance trough level is 5 to 10 ng/mL.,Sirolimus Dose Requirement in Kidney Transplant Recipients in Iran. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277457/),[ng] / [ml],5 to 10,203094,DB00877,Sirolimus
,23735180,Cmax,The mean (range) Cmax values of the test and the reference were 15.25 (8.48 - 24.40) and 13.43 (7.90 - 22.90) ng/ml; AUC0-t values were 475.65 (293.33 - 1049.86) and 451.96 (221.52 - 809.11) ng/h/ml.,Comparative bioavailability and pharmacokinetics of sirolimus tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735180/),[ng] / [ml],15.25,206693,DB00877,Sirolimus
,23735180,Cmax,The mean (range) Cmax values of the test and the reference were 15.25 (8.48 - 24.40) and 13.43 (7.90 - 22.90) ng/ml; AUC0-t values were 475.65 (293.33 - 1049.86) and 451.96 (221.52 - 809.11) ng/h/ml.,Comparative bioavailability and pharmacokinetics of sirolimus tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735180/),[ng] / [ml],13.43,206694,DB00877,Sirolimus
,23735180,AUC0-t,The mean (range) Cmax values of the test and the reference were 15.25 (8.48 - 24.40) and 13.43 (7.90 - 22.90) ng/ml; AUC0-t values were 475.65 (293.33 - 1049.86) and 451.96 (221.52 - 809.11) ng/h/ml.,Comparative bioavailability and pharmacokinetics of sirolimus tablets in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735180/),[ng] / [h·ml],475.65,206695,DB00877,Sirolimus
,23735180,AUC0-t,The mean (range) Cmax values of the test and the reference were 15.25 (8.48 - 24.40) and 13.43 (7.90 - 22.90) ng/ml; AUC0-t values were 475.65 (293.33 - 1049.86) and 451.96 (221.52 - 809.11) ng/h/ml.,Comparative bioavailability and pharmacokinetics of sirolimus tablets in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735180/),[ng] / [h·ml],451.96,206696,DB00877,Sirolimus
,23735180,tmax,"The medians (range) tmax values were 2.0 (1.0 - 8.0) and 2.0 (1.0 - 8.0) hours, respectively.",Comparative bioavailability and pharmacokinetics of sirolimus tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735180/),h,2.0,206697,DB00877,Sirolimus
,11180036,area under the plasma concentration time-curve,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),[h·ng] / [ml],736,207301,DB00877,Sirolimus
,11180036,maximum concentration,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),[ng] / [ml],67,207302,DB00877,Sirolimus
,11180036,elimination half-life,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),h,79,207303,DB00877,Sirolimus
,11180036,elimination half-life,"The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180036/),h,67,207304,DB00877,Sirolimus
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.31,209092,DB00877,Sirolimus
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.76,209093,DB00877,Sirolimus
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],24.1,209094,DB00877,Sirolimus
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],22.8,209095,DB00877,Sirolimus
,28194539,MTD,"Nine patients had dose-limiting toxicities (stomatitis, thrombocytopenia, serum creatinine phosphokinase increase, visual impairment) and the MTD was determined as 45 mg/day pimasertib plus 25 mg/week temsirolimus.",Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28194539/),mg,45,209857,DB00877,Sirolimus
,20137762,C(max),Coadministration of everolimus decreased sotrastaurin C(max) from 638 +/- 295 to 539 +/- 211 ng/ml yielding a combination/ monotherapy ratio (90% confidence interval) of 0.87 (0.76 - 1.00).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],638,210638,DB00877,Sirolimus
,20137762,C(max),Coadministration of everolimus decreased sotrastaurin C(max) from 638 +/- 295 to 539 +/- 211 ng/ml yielding a combination/ monotherapy ratio (90% confidence interval) of 0.87 (0.76 - 1.00).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],539,210639,DB00877,Sirolimus
,20137762,total AUC,Sotrastaurin total AUC was not altered by everolimus with values of 3660 +/- 1853 versus 3630 +/- 2006 ng*h/ml and a ratio of 1.00 (0.88 - 1.13).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],3660,210640,DB00877,Sirolimus
,20137762,total AUC,Sotrastaurin total AUC was not altered by everolimus with values of 3660 +/- 1853 versus 3630 +/- 2006 ng*h/ml and a ratio of 1.00 (0.88 - 1.13).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],3630,210641,DB00877,Sirolimus
,20137762,C(max),Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],15,210642,DB00877,Sirolimus
,20137762,C(max),Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[ng] / [ml],16,210643,DB00877,Sirolimus
,20137762,total AUC,Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],114,210644,DB00877,Sirolimus
,20137762,total AUC,Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37).,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137762/),[h·ng] / [ml],137,210645,DB00877,Sirolimus
,20430774,maximum-tolerated dose,The maximum-tolerated dose was 15 mg/m(2).,A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430774/),[mg] / [m],15,213036,DB00877,Sirolimus
,16860172,AUCs,"In patients receiving CsA/MMF, MPA AUCs ranged from 19.67 to 81.80 mg/h.L (mean [SD], 41.92 [14.14] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],19.67 to 81.80,213191,DB00877,Sirolimus
,16860172,AUCs,"In patients receiving CsA/MMF, MPA AUCs ranged from 19.67 to 81.80 mg/h.L (mean [SD], 41.92 [14.14] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],41.92,213192,DB00877,Sirolimus
<,16860172,AUCs,"Co levels of 0.5 and 1.6 mg/L were correlated with AUCs of <30 and <40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],30,213193,DB00877,Sirolimus
<,16860172,AUCs,"Co levels of 0.5 and 1.6 mg/L were correlated with AUCs of <30 and <40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],40,213194,DB00877,Sirolimus
,16860172,AUCs,"In patients receiving RAPA/MMF, MPA AUCs ranged from 34.40 to 87.60 mg/h.L (mean, 51.07 [15.80] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],51.07,213195,DB00877,Sirolimus
,16860172,C0,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [l],1.0,213196,DB00877,Sirolimus
,16860172,C0,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [l],2.3,213197,DB00877,Sirolimus
,16860172,AUCs,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],30,213198,DB00877,Sirolimus
,16860172,AUCs,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],40,213199,DB00877,Sirolimus
,16860172,AUC,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·h·l],60.95,213200,DB00877,Sirolimus
,16860172,AUC,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·h·l],31.92,213201,DB00877,Sirolimus
,16860172,C0,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·l],5.10,213202,DB00877,Sirolimus
,16860172,C0,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·l],1.41,213203,DB00877,Sirolimus
,22459565,time to radiological progression,Median time to radiological progression and overall survival were 15.3 weeks (range: 8.2-173.9) and 26.4 weeks (range: 8.2-173.9) respectively.,Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22459565/),weeks,15.3,218209,DB00877,Sirolimus
,22459565,overall survival,Median time to radiological progression and overall survival were 15.3 weeks (range: 8.2-173.9) and 26.4 weeks (range: 8.2-173.9) respectively.,Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22459565/),weeks,26.4,218210,DB00877,Sirolimus
,27310200,half maximal inhibitory concentration,"Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 µM) rather than CYP3A5 (>5 µM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 µM) and CYP3A5 (0.41 µM).",Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310200/),μM,0.71,219176,DB00877,Sirolimus
>,27310200,half maximal inhibitory concentration,"Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 µM) rather than CYP3A5 (>5 µM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 µM) and CYP3A5 (0.41 µM).",Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310200/),,5,219177,DB00877,Sirolimus
,16029064,trough,"If ciclosporin therapy is discontinued, a target trough range of 12-20 microg/L is recommended.",Sirolimus: the evidence for clinical pharmacokinetic monitoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029064/),[μg] / [l],12-20,219893,DB00877,Sirolimus
,9443858,degradation half-life,"Sirolimus degradation half-life in whole blood was 135 hr (vs. 7.2 hr in plasma) in humans, 62 hr (vs. 3.1 hr) in rabbits, and 15 hr (vs. 2.2 hr) in rats.","Species differences in sirolimus stability in humans, rabbits, and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443858/),h,135,220376,DB00877,Sirolimus
,9443858,degradation half-life,"Sirolimus degradation half-life in whole blood was 135 hr (vs. 7.2 hr in plasma) in humans, 62 hr (vs. 3.1 hr) in rabbits, and 15 hr (vs. 2.2 hr) in rats.","Species differences in sirolimus stability in humans, rabbits, and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443858/),h,7.2,220377,DB00877,Sirolimus
,9443858,degradation half-life,"Sirolimus degradation half-life in whole blood was 135 hr (vs. 7.2 hr in plasma) in humans, 62 hr (vs. 3.1 hr) in rabbits, and 15 hr (vs. 2.2 hr) in rats.","Species differences in sirolimus stability in humans, rabbits, and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443858/),h,62,220378,DB00877,Sirolimus
,9443858,degradation half-life,"Sirolimus degradation half-life in whole blood was 135 hr (vs. 7.2 hr in plasma) in humans, 62 hr (vs. 3.1 hr) in rabbits, and 15 hr (vs. 2.2 hr) in rats.","Species differences in sirolimus stability in humans, rabbits, and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443858/),h,3.1,220379,DB00877,Sirolimus
,9443858,degradation half-life,"Sirolimus degradation half-life in whole blood was 135 hr (vs. 7.2 hr in plasma) in humans, 62 hr (vs. 3.1 hr) in rabbits, and 15 hr (vs. 2.2 hr) in rats.","Species differences in sirolimus stability in humans, rabbits, and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443858/),h,15,220380,DB00877,Sirolimus
,9443858,degradation half-life,"Sirolimus degradation half-life in whole blood was 135 hr (vs. 7.2 hr in plasma) in humans, 62 hr (vs. 3.1 hr) in rabbits, and 15 hr (vs. 2.2 hr) in rats.","Species differences in sirolimus stability in humans, rabbits, and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443858/),h,2.2,220381,DB00877,Sirolimus
,17048977,transfer rate constant,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),1/[h],5.25,221778,DB00877,Sirolimus
,17048977,transfer rate constant,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),l,218,221779,DB00877,Sirolimus
,17048977,apparent volume of,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),l,218,221780,DB00877,Sirolimus
,17048977,apparent volume of,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),l,292,221781,DB00877,Sirolimus
,17048977,oral clearance,The CYP3A5*1/*3 polymorphism significantly influenced the apparent oral clearance: mean oral clearance = 14.1 L/h for CYP3A5 non expressers (CYP3A5*3/*3 genotype) versus 28.3 L/h for CYP3A5 expressers (CYP3A5*1/*3 and *1/*1 genotypes).,Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),[l] / [h],14.1,221782,DB00877,Sirolimus
,17048977,oral clearance,The CYP3A5*1/*3 polymorphism significantly influenced the apparent oral clearance: mean oral clearance = 14.1 L/h for CYP3A5 non expressers (CYP3A5*3/*3 genotype) versus 28.3 L/h for CYP3A5 expressers (CYP3A5*1/*3 and *1/*1 genotypes).,Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),[l] / [h],28.3,221783,DB00877,Sirolimus
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],5.2,222537,DB00877,Sirolimus
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],9.4,222538,DB00877,Sirolimus
> or =,15575918,trough levels,Biopsy-proven acute rejection (BPAR) was reduced with everolimus trough levels > or =3 ng/mL.,Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],3,222539,DB00877,Sirolimus
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),[ml] / [kg·min],50,223122,DB00877,Sirolimus
,19790241,hepatic blood flow,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223123,DB00877,Sirolimus
,19790241,apparent intestinal,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,80,223124,DB00877,Sirolimus
,19790241,hepatic extraction,"Using a value for hepatic blood flow from the literature (50 ml/min/kg), the apparent intestinal and hepatic extraction of everolimus without itraconazole was calculated as about 80% and 13%, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),%,13,223125,DB00877,Sirolimus
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.829,223126,DB00877,Sirolimus
,19790241,apparent intestinal extraction,"Intraintestinally administered itraconazole (20 mg/kg) changed the apparent intestinal extraction by 0.26-fold from 0.829 to 0.215, but the hepatic availability of everolimus was almost unchanged after the intravenous or intraintestinal administration of itraconazole even at a dose of 50 mg/kg from 0.871 to 0.923 or 0.867, respectively.",Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19790241/),,0.215,223127,DB00877,Sirolimus
,24057042,MTD,"The MTD of the combination was 1,250 mg of lapatinib and 5 mg of everolimus once daily.",Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24057042/),mg,"1,250",223212,DB00877,Sirolimus
,19196220,maximum plasma concentration (C(max)),"Mean (% coefficient of variation) maximum plasma concentration (C(max)) and area under the curve (AUC) of sirolimus at day 1 were 4.9 ng/mL (38) and 145 h x ng/mL (45), respectively.",Effects of oral posaconazole on the pharmacokinetics of sirolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19196220/),[ng] / [ml],4.9,223808,DB00877,Sirolimus
,19196220,area under the curve (AUC),"Mean (% coefficient of variation) maximum plasma concentration (C(max)) and area under the curve (AUC) of sirolimus at day 1 were 4.9 ng/mL (38) and 145 h x ng/mL (45), respectively.",Effects of oral posaconazole on the pharmacokinetics of sirolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19196220/),[h·ng] / [ml],145,223809,DB00877,Sirolimus
,17203553,time after dose,"A total of 31 patients (7 female and 24 male) originally included in a formal clinical trial, contributed 524 sirolimus blood concentrations with the time after dose ranging from 11.08 to 31.83 hours.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203553/),h,11.08 to 31.83,226648,DB00877,Sirolimus
,17203553,CL/F,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203553/),[l] / [h],7.09,226649,DB00877,Sirolimus
,17203553,apparent volume of distribution,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203553/),[l] / [h],1350,226650,DB00877,Sirolimus
,19656203,AUC,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,8066,227366,DB00877,Sirolimus
,19656203,AUC,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,6699,227367,DB00877,Sirolimus
,19656203,C0,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,272,227368,DB00877,Sirolimus
,19656203,C0,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,245,227369,DB00877,Sirolimus
,19656203,AUC,A fivefold increase in SRL AUC (from a mean of 130 to 538 ng h/mL) was associated with a 25% increase in mean a.m.,Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],130 to 538,227370,DB00877,Sirolimus
,19656203,AUC,"CsA AUC [7021 to 8811 ng h/mL, P = 0.037, CI (-3461.2; -118.9)] and with a 42% increase in mean p.m. CsA AUC [5386-7639, P = 0.024, CI (-4164.4; -340.7)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],7021,227371,DB00877,Sirolimus
,19656203,AUC,"CsA AUC [7021 to 8811 ng h/mL, P = 0.037, CI (-3461.2; -118.9)] and with a 42% increase in mean p.m. CsA AUC [5386-7639, P = 0.024, CI (-4164.4; -340.7)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],8811,227372,DB00877,Sirolimus
,19656203,AUC,"CsA AUC (from 5860 to 10 974 ng h/mL) was associated with a 70% increase in mean SRL AUC [223 to 380 ng h/mL, P = 0.0026, CI (-291.7; -22.8)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],5860 to 10 974,227373,DB00877,Sirolimus
,19656203,AUC,"CsA AUC (from 5860 to 10 974 ng h/mL) was associated with a 70% increase in mean SRL AUC [223 to 380 ng h/mL, P = 0.0026, CI (-291.7; -22.8)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],223 to 380,227374,DB00877,Sirolimus
,19656203,AUC,"A twofold increase in p.m. CsA AUC (from 4573 to 9692 ng h/mL) was associated with a 63% increase in mean SRL AUC [246 to 400 ng h/mL, P = 0.032, CI (-290.7; -16.6)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],4573 to 9692,227375,DB00877,Sirolimus
,19656203,AUC,"A twofold increase in p.m. CsA AUC (from 4573 to 9692 ng h/mL) was associated with a 63% increase in mean SRL AUC [246 to 400 ng h/mL, P = 0.032, CI (-290.7; -16.6)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],246,227376,DB00877,Sirolimus
,19656203,AUC,"A twofold increase in p.m. CsA AUC (from 4573 to 9692 ng h/mL) was associated with a 63% increase in mean SRL AUC [246 to 400 ng h/mL, P = 0.032, CI (-290.7; -16.6)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],400,227377,DB00877,Sirolimus
,10533695,plasma clearance,Mean Pred plasma clearance was 0.655 L/hr (interrat++ variability: 11%) and significantly increased with weight.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),[l] / [h],0.655,227701,DB00877,Sirolimus
,10533695,whole blood volume of distribution,"Mean SIR whole blood volume of distribution and clearance were 5.6 L (62%) and 0.28 L/hr (32%), and animal scaling showed weight-power proportionality.",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),l,5.6,227702,DB00877,Sirolimus
,10533695,clearance,"Mean SIR whole blood volume of distribution and clearance were 5.6 L (62%) and 0.28 L/hr (32%), and animal scaling showed weight-power proportionality.",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),[l] / [h],0.28,227703,DB00877,Sirolimus
,10533695,IC50,Pred decreased numbers of T-helper lymphocytes with a mean IC50 of 37.8 nM (21%) alone or 12.3 nM (130%) with SIR.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,37.8,227704,DB00877,Sirolimus
,10533695,IC50,Pred decreased numbers of T-helper lymphocytes with a mean IC50 of 37.8 nM (21%) alone or 12.3 nM (130%) with SIR.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,12.3,227705,DB00877,Sirolimus
,10533695,IC50,SIR increased lymphocyte numbers with a mean IC50 of 52.2 nM (24%) for T-helper and 28.8 nM (51%) for T-cytotoxic cells.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,52.2,227706,DB00877,Sirolimus
,10533695,IC50,SIR increased lymphocyte numbers with a mean IC50 of 52.2 nM (24%) for T-helper and 28.8 nM (51%) for T-cytotoxic cells.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,28.8,227707,DB00877,Sirolimus
,10533695,IC50,"Taking into account drug effects on lymphocyte trafficking, Pred directly inhibited ex vivo lymphocyte proliferation with a mean IC50 of 1.08 nM (38%).",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,1.08,227708,DB00877,Sirolimus
,10533695,IC50,"SIR, after a transduction step, inhibited proliferation with a mean IC50 of 1.00 nM (26%).",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,1.00,227709,DB00877,Sirolimus
,28700521,AUC0-144,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],315.2,227868,DB00877,Sirolimus
,28700521,AUC0-144,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],440.8,227869,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],372.0,227870,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],10.2,227871,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],440.8,227872,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],537.4,227873,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],13.7,227874,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],540.2,227875,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],626.6,227876,DB00877,Sirolimus
,28700521,AUC0-∞,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],19.8,227877,DB00877,Sirolimus
,28700521,Cmax,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],10.2,227878,DB00877,Sirolimus
,28700521,Cmax,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],13.7,227879,DB00877,Sirolimus
,28700521,Cmax,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],540.2,227880,DB00877,Sirolimus
,28700521,Cmax,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],626.6,227881,DB00877,Sirolimus
,28700521,Cmax,"Briefly, the AUC0-144, AUC0-∞, and Cmax of *1G/*1G carrier were 315.2 ± 91.5, 372.0 ± 108.2, and 10.2 ± 1.6 ng/mL, respectively, and those of *1/*1 G*1/*1 G carrier were 440.8 ± 130.6, 537.4 ± 167.5, and 13.7 ± 4.3, respectively, whereas those of CYP3A4*1/*1 homozygous subjects were 540.2 ± 150.6, 626.6 ± 166.9, and 19.8 ± 7.5 ng/mL, respectively.",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],19.8,227882,DB00877,Sirolimus
,28700521,AUC0-144,"In CYP3A5-nonexpressing subjects (*3/*3 homozygous carriers, n = 15), the AUC0-144 and Cmax were 549.6 ± 137.9 and 19.9 ± 7.9 ng/mL, respectively, and were significantly higher (P < 0.05) than the values in CYP3A5-expressing subjects (*1/*1homozygous carrier, n = 2; 314.2 ± 129.3 and 10.3 ± 2.2 ng/mL; *1/*3 heterozygous carrier, n = 15; 440.2 ± 146.3 and 14.6 ± 5.1 ng/mL, respectively).",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],549.6,227883,DB00877,Sirolimus
,28700521,AUC0-144,"In CYP3A5-nonexpressing subjects (*3/*3 homozygous carriers, n = 15), the AUC0-144 and Cmax were 549.6 ± 137.9 and 19.9 ± 7.9 ng/mL, respectively, and were significantly higher (P < 0.05) than the values in CYP3A5-expressing subjects (*1/*1homozygous carrier, n = 2; 314.2 ± 129.3 and 10.3 ± 2.2 ng/mL; *1/*3 heterozygous carrier, n = 15; 440.2 ± 146.3 and 14.6 ± 5.1 ng/mL, respectively).",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],314.2,227884,DB00877,Sirolimus
,28700521,AUC0-144,"In CYP3A5-nonexpressing subjects (*3/*3 homozygous carriers, n = 15), the AUC0-144 and Cmax were 549.6 ± 137.9 and 19.9 ± 7.9 ng/mL, respectively, and were significantly higher (P < 0.05) than the values in CYP3A5-expressing subjects (*1/*1homozygous carrier, n = 2; 314.2 ± 129.3 and 10.3 ± 2.2 ng/mL; *1/*3 heterozygous carrier, n = 15; 440.2 ± 146.3 and 14.6 ± 5.1 ng/mL, respectively).",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],440.2,227885,DB00877,Sirolimus
,28700521,Cmax,"In CYP3A5-nonexpressing subjects (*3/*3 homozygous carriers, n = 15), the AUC0-144 and Cmax were 549.6 ± 137.9 and 19.9 ± 7.9 ng/mL, respectively, and were significantly higher (P < 0.05) than the values in CYP3A5-expressing subjects (*1/*1homozygous carrier, n = 2; 314.2 ± 129.3 and 10.3 ± 2.2 ng/mL; *1/*3 heterozygous carrier, n = 15; 440.2 ± 146.3 and 14.6 ± 5.1 ng/mL, respectively).",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],19.9,227886,DB00877,Sirolimus
,28700521,Cmax,"In CYP3A5-nonexpressing subjects (*3/*3 homozygous carriers, n = 15), the AUC0-144 and Cmax were 549.6 ± 137.9 and 19.9 ± 7.9 ng/mL, respectively, and were significantly higher (P < 0.05) than the values in CYP3A5-expressing subjects (*1/*1homozygous carrier, n = 2; 314.2 ± 129.3 and 10.3 ± 2.2 ng/mL; *1/*3 heterozygous carrier, n = 15; 440.2 ± 146.3 and 14.6 ± 5.1 ng/mL, respectively).",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],10.3,227887,DB00877,Sirolimus
,28700521,Cmax,"In CYP3A5-nonexpressing subjects (*3/*3 homozygous carriers, n = 15), the AUC0-144 and Cmax were 549.6 ± 137.9 and 19.9 ± 7.9 ng/mL, respectively, and were significantly higher (P < 0.05) than the values in CYP3A5-expressing subjects (*1/*1homozygous carrier, n = 2; 314.2 ± 129.3 and 10.3 ± 2.2 ng/mL; *1/*3 heterozygous carrier, n = 15; 440.2 ± 146.3 and 14.6 ± 5.1 ng/mL, respectively).",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],440.2,227888,DB00877,Sirolimus
,28700521,Cmax,"In CYP3A5-nonexpressing subjects (*3/*3 homozygous carriers, n = 15), the AUC0-144 and Cmax were 549.6 ± 137.9 and 19.9 ± 7.9 ng/mL, respectively, and were significantly higher (P < 0.05) than the values in CYP3A5-expressing subjects (*1/*1homozygous carrier, n = 2; 314.2 ± 129.3 and 10.3 ± 2.2 ng/mL; *1/*3 heterozygous carrier, n = 15; 440.2 ± 146.3 and 14.6 ± 5.1 ng/mL, respectively).",Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28700521/),[ng] / [ml],14.6,227889,DB00877,Sirolimus
,15136596,steady-state volume of distribution,Mean steady-state volume of distribution ranged from 127 to 385L.,"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15136596/),l,127 to 385,228282,DB00877,Sirolimus
,15136596,metabolite-to-parent ratio,"Sirolimus was a major metabolite (metabolite-to-parent ratio range, 2.5 to 3.5).","Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15136596/),,2.5 to 3.5,228283,DB00877,Sirolimus
,15136596,Whole blood clearance,"Whole blood clearance was nonlinear, ranging from 19 to 51 L/h (34 to 220 mg/m(2)).","Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15136596/),[l] / [h],19 to 51,228284,DB00877,Sirolimus
,15136596,Whole blood clearance,"Whole blood clearance was nonlinear, ranging from 19 to 51 L/h (34 to 220 mg/m(2)).","Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15136596/),[mg] / [m(2],34 to 220,228285,DB00877,Sirolimus
,23266742,trough level before the dose (C0),"The mean ± SD sirolimus trough level before the dose (C0) was 8.0 ± 4.6 ng/mL (range, 1.8-21.6 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],8.0,230288,DB00877,Sirolimus
,23266742,peak concentration,"The peak concentration was 19.9 ± 11.8 ng/mL (range, 3.9-46.1 ng/mL), and the trough level 24 hours later (C24) was 9.1 ± 5.3 ng/mL (range, 1.0-19.1 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],19.9,230289,DB00877,Sirolimus
,23266742,trough level,"The peak concentration was 19.9 ± 11.8 ng/mL (range, 3.9-46.1 ng/mL), and the trough level 24 hours later (C24) was 9.1 ± 5.3 ng/mL (range, 1.0-19.1 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],9.1,230290,DB00877,Sirolimus
,23266742,C24),"The peak concentration was 19.9 ± 11.8 ng/mL (range, 3.9-46.1 ng/mL), and the trough level 24 hours later (C24) was 9.1 ± 5.3 ng/mL (range, 1.0-19.1 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],9.1,230291,DB00877,Sirolimus
,23266742,terminal disposition half-life (T1/2),"The terminal disposition half-life (T1/2) was 24.5 ± 11.2 hours (range, 5.8-53.2 hours), and the area under the concentration-versus-time curve (AUC0-24) was 401.1 ± 316.3 ng·h/mL (range, 20.7-1332.3 ng·h/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),h,24.5,230292,DB00877,Sirolimus
,23266742,area under the concentration-versus-time curve (AUC0-24),"The terminal disposition half-life (T1/2) was 24.5 ± 11.2 hours (range, 5.8-53.2 hours), and the area under the concentration-versus-time curve (AUC0-24) was 401.1 ± 316.3 ng·h/mL (range, 20.7-1332.3 ng·h/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[h·ng] / [ml],401.1,230293,DB00877,Sirolimus
,23266742,C24,C24 was significantly lower in patients (n = 10) who developed grade III-IV aGVHD (n = 10) than in those with grade 0-II aGVHD (n = 22) (6.1 ± 2.9 ng/mL versus 9.4 ± 5.5 ng/mL; P = .044).,Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],6.1,230294,DB00877,Sirolimus
,23266742,C24,C24 was significantly lower in patients (n = 10) who developed grade III-IV aGVHD (n = 10) than in those with grade 0-II aGVHD (n = 22) (6.1 ± 2.9 ng/mL versus 9.4 ± 5.5 ng/mL; P = .044).,Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],9.4,230295,DB00877,Sirolimus
,23266742,C0,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],3.9,230296,DB00877,Sirolimus
,23266742,C0,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],2.4,230297,DB00877,Sirolimus
,23266742,C24,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],4.8,230298,DB00877,Sirolimus
,23266742,C24,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],2.5,230299,DB00877,Sirolimus
,23266742,trough levels,"With therapeutic drug monitoring, the majority (79%) of sirolimus trough levels could be maintained within the target range (3-12 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],3-12,230300,DB00877,Sirolimus
,22878749,overall response rate,"One patient had a partial response to erlotinib/HCQ, for an overall response rate of 5% (95% confidence interval, 1-25).",A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22878749/),%,5,230952,DB00877,Sirolimus
,27530708,IC50,"We were able to describe well the interaction, and found a value of IC50 of posaconazole towards sirolimus clearance of 0.68 μg/mL.",Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530708/),[μg] / [ml],0.68,231115,DB00877,Sirolimus
,27530708,trough concentrations,The simulations showed that even a 80% decrease of the daily dose of sirolimus is unsuitable in many cases with trough concentrations of posaconazole of 2 μg/mL.,Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530708/),[μg] / [ml],2,231116,DB00877,Sirolimus
,27661398,apparent oral clearance,Everolimus pharmacokinetics was best described by a 2-compartment model with population mean estimates of apparent oral clearance of 10.0 L/h and an interindividual variability of 42.4%.,Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),[l] / [h],10.0,231150,DB00877,Sirolimus
,27661398,trough concentration,The predicted trough concentration in patients who terminated everolimus treatment owing to adverse drug reactions (ADRs) was significantly higher than in patients who stopped the treatment owing to disease progression or other reasons (27.6 ± 3.1 versus 15.7 ± 2.3 ng/mL; mean ± SEM).,Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),[ng] / [ml],27.6,231151,DB00877,Sirolimus
,27661398,trough concentration,The predicted trough concentration in patients who terminated everolimus treatment owing to adverse drug reactions (ADRs) was significantly higher than in patients who stopped the treatment owing to disease progression or other reasons (27.6 ± 3.1 versus 15.7 ± 2.3 ng/mL; mean ± SEM).,Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),[ng] / [ml],15.7,231152,DB00877,Sirolimus
,27661398,time-to-treatment failure,"Patients who terminated the treatment owing to ADRs had significantly shorter time-to-treatment failure than other patients (112 versus 187 days, median).",Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),d,112,231153,DB00877,Sirolimus
,27661398,time-to-treatment failure,"Patients who terminated the treatment owing to ADRs had significantly shorter time-to-treatment failure than other patients (112 versus 187 days, median).",Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27661398/),d,187,231154,DB00877,Sirolimus
,22850296,oral relative bioavailability,Pharmacokinetic study in beagle dogs showed the oral relative bioavailability of SRL-SMEDDS pellets to the commercial SRL tablets Rapamune was about 136.9%.,"Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22850296/),%,136.9,232895,DB00877,Sirolimus
,23018254,dose,The mean cyclosporine dose-adjusted trough blood concentrations (ng/ml per mg/kg body weight) in CYP3A4*1/*1B subjects were lower than in the CYP3A4*1/*1 group (37.06±10.38 vs. 44.63±13.99; p<0.218).,Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018254/),[ng] / [kg·mg·ml],37.06,233701,DB00877,Sirolimus
,23018254,trough blood concentrations,The mean cyclosporine dose-adjusted trough blood concentrations (ng/ml per mg/kg body weight) in CYP3A4*1/*1B subjects were lower than in the CYP3A4*1/*1 group (37.06±10.38 vs. 44.63±13.99; p<0.218).,Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018254/),[ng] / [kg·mg·ml],37.06,233702,DB00877,Sirolimus
,23018254,trough blood concentrations,The mean cyclosporine dose-adjusted trough blood concentrations (ng/ml per mg/kg body weight) in CYP3A4*1/*1B subjects were lower than in the CYP3A4*1/*1 group (37.06±10.38 vs. 44.63±13.99; p<0.218).,Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018254/),[ng] / [kg·mg·ml],44.63,233703,DB00877,Sirolimus
,17038957,maximum concentration,"Systemic sirolimus levels peaked between 1 and 7 hours postimplant (maximum concentration, 1.2 +/- 1.47, 79 microg; 4.5 +/- 1.23 ng/ml, 479 microg), then declined rapidly to 1 ng/ml or less by 96 hours.",Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038957/),μg,1.2,234964,DB00877,Sirolimus
,17038957,maximum concentration,"Systemic sirolimus levels peaked between 1 and 7 hours postimplant (maximum concentration, 1.2 +/- 1.47, 79 microg; 4.5 +/- 1.23 ng/ml, 479 microg), then declined rapidly to 1 ng/ml or less by 96 hours.",Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038957/),[ng] / [ml],4.5,234965,DB00877,Sirolimus
,17038957,maximum concentration,"Systemic sirolimus levels peaked between 1 and 7 hours postimplant (maximum concentration, 1.2 +/- 1.47, 79 microg; 4.5 +/- 1.23 ng/ml, 479 microg), then declined rapidly to 1 ng/ml or less by 96 hours.",Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038957/),μg,479,234966,DB00877,Sirolimus
,17038957,Peak local tissue sirolimus levels,Peak local tissue sirolimus levels were 41.5 ng/mg (79 microg) and 65 ng/mg (479 microg).,Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038957/),[ng] / [mg],41.5,234967,DB00877,Sirolimus
,17038957,Peak local tissue sirolimus levels,Peak local tissue sirolimus levels were 41.5 ng/mg (79 microg) and 65 ng/mg (479 microg).,Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038957/),[ng] / [mg],65,234968,DB00877,Sirolimus
,25467181,AUC,"At 8 mg/m(2), the median temsirolimus AUC was 2,946 ng • h/mL (range, 937-5,536) with a median sirolimus AUC of 767 ng • h/mL (range, 245-3,675).",A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25467181/),[h·ng] / [ml],"2,946",235616,DB00877,Sirolimus
,25467181,AUC,"At 8 mg/m(2), the median temsirolimus AUC was 2,946 ng • h/mL (range, 937-5,536) with a median sirolimus AUC of 767 ng • h/mL (range, 245-3,675).",A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25467181/),[h·ng] / [ml],767,235617,DB00877,Sirolimus
,32438078,Ctrough,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],30-61,235704,DB00877,Sirolimus
,32438078,Cpeak,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],143-449,235705,DB00877,Sirolimus
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-13,235706,DB00877,Sirolimus
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-16,235707,DB00877,Sirolimus
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-11,235708,DB00877,Sirolimus
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],5-17,235709,DB00877,Sirolimus
,24908540,response rate,The response rate at the MDT was 1/15 (7%) while the progression free survival for the MTD was 7 months (95% confidence interval (CI) 2.2-11 months).,A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24908540/),,1,238101,DB00877,Sirolimus
,24908540,progression free survival,The response rate at the MDT was 1/15 (7%) while the progression free survival for the MTD was 7 months (95% confidence interval (CI) 2.2-11 months).,A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24908540/),month,7,238102,DB00877,Sirolimus
,31452734,apparent oral clearance (CL/F),"The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 3.19 l/h and 165 liters, respectively.",Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452734/),[l] / [h],3.19,238188,DB00877,Sirolimus
,31452734,apparent volume of distribution (V/F),"The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 3.19 l/h and 165 liters, respectively.",Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452734/),l,165,238189,DB00877,Sirolimus
,10220493,systemic clearance,"After i.v. administration of 1 mg/kg SDZ-RAD or rapamycin, the area under the concentration curve (AUC) for rapamycin was twice that of SDZ-RAD, resulting in a systemic clearance of 6.2 ml/min and 3.0 ml/min for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[ml] / [min],6.2,238419,DB00877,Sirolimus
,10220493,systemic clearance,"After i.v. administration of 1 mg/kg SDZ-RAD or rapamycin, the area under the concentration curve (AUC) for rapamycin was twice that of SDZ-RAD, resulting in a systemic clearance of 6.2 ml/min and 3.0 ml/min for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[ml] / [min],3.0,238420,DB00877,Sirolimus
,10220493,AUC for oral absorption,"However, the AUC for oral absorption was similar for the two compounds: 140 and 172 ng*h/ml for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[h·ng] / [ml],140,238421,DB00877,Sirolimus
,10220493,AUC for oral absorption,"However, the AUC for oral absorption was similar for the two compounds: 140 and 172 ng*h/ml for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[h·ng] / [ml],172,238422,DB00877,Sirolimus
,10220493,absolute oral bioavailability,"Because blood clearance was faster for SDZ-RAD after i.v. administration, the absolute oral bioavailability for SDZ-RAD was 16% compared with 10% for rapamycin.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),%,16,238423,DB00877,Sirolimus
,10220493,absolute oral bioavailability,"Because blood clearance was faster for SDZ-RAD after i.v. administration, the absolute oral bioavailability for SDZ-RAD was 16% compared with 10% for rapamycin.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),%,10,238424,DB00877,Sirolimus
,17504225,trough blood concentrations,"In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.",A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17504225/),[ng] / [ml],6.,239005,DB00877,Sirolimus
,17504225,trough blood concentrations,"In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.",A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17504225/),[ng] / [ml],54,239006,DB00877,Sirolimus
,28245187,SRL,CYP3A5*1/*3 showed lower SRL levels than CYP3A5*3/*3 (4.13±1.54 vs. 8.49±4.18 ng/mL; p=0.003) and level/dose ratio (LDR) (92.74±37.47 vs. 178.62±116.45; p=0.019) in early post-transplant period.,"Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),[ng] / [ml],4.13,240663,DB00877,Sirolimus
,28245187,SRL,CYP3A5*1/*3 showed lower SRL levels than CYP3A5*3/*3 (4.13±1.54 vs. 8.49±4.18 ng/mL; p=0.003) and level/dose ratio (LDR) (92.74±37.47 vs. 178.62±116.45; p=0.019) in early post-transplant period.,"Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),[ng] / [ml],8.49,240664,DB00877,Sirolimus
,28245187,level/dose ratio (LDR),CYP3A5*1/*3 showed lower SRL levels than CYP3A5*3/*3 (4.13±1.54 vs. 8.49±4.18 ng/mL; p=0.003) and level/dose ratio (LDR) (92.74±37.47 vs. 178.62±116.45; p=0.019) in early post-transplant period.,"Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),,92.74,240665,DB00877,Sirolimus
,28245187,level/dose ratio (LDR),CYP3A5*1/*3 showed lower SRL levels than CYP3A5*3/*3 (4.13±1.54 vs. 8.49±4.18 ng/mL; p=0.003) and level/dose ratio (LDR) (92.74±37.47 vs. 178.62±116.45; p=0.019) in early post-transplant period.,"Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),,178.62,240666,DB00877,Sirolimus
,28245187,LDR,"In ABCB1 polymorphisms, CT genotypes showed higher SRL levels than CC and TT (8.93±2.22 vs. 7.28±2.47 vs. 7.35±1.15 ng/mL; p=0.038) in the late period; LDR in CC and CT were 171.29±36.24 vs. 335.66±138.71 (p=0.003), despite receiving lower doses (p=0.018).","Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),,171.29,240667,DB00877,Sirolimus
,28245187,LDR,"In ABCB1 polymorphisms, CT genotypes showed higher SRL levels than CC and TT (8.93±2.22 vs. 7.28±2.47 vs. 7.35±1.15 ng/mL; p=0.038) in the late period; LDR in CC and CT were 171.29±36.24 vs. 335.66±138.71 (p=0.003), despite receiving lower doses (p=0.018).","Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),,335.66,240668,DB00877,Sirolimus
,28245187,Acute rejection rate,"Acute rejection rate was 14% vs. 42% for *3/*3 and 14% (TT), 48% (CT), and 31% (CC).","Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),%,14,240669,DB00877,Sirolimus
,28245187,Acute rejection rate,"Acute rejection rate was 14% vs. 42% for *3/*3 and 14% (TT), 48% (CT), and 31% (CC).","Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),%,42,240670,DB00877,Sirolimus
,28245187,Acute rejection rate,"Acute rejection rate was 14% vs. 42% for *3/*3 and 14% (TT), 48% (CT), and 31% (CC).","Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),%,48,240671,DB00877,Sirolimus
,28245187,Acute rejection rate,"Acute rejection rate was 14% vs. 42% for *3/*3 and 14% (TT), 48% (CT), and 31% (CC).","Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28245187/),%,31,240672,DB00877,Sirolimus
,14629289,Cmin,Everolimus Cmin averaged 9-11 ng/mL in the immediate cyclosporine group over the first 3 months.,Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],9-11,240928,DB00877,Sirolimus
,14629289,Cmins,"In the delayed cyclosporine group, average everolimus Cmins were significantly lower by 2.9-fold in the absence vs. presence of cyclosporine: 2.9 +/- 2.8 vs. 8.3 +/- 3.7 ng/mL (p < 0.001).",Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],2.9,240929,DB00877,Sirolimus
,14629289,Cmins,"In the delayed cyclosporine group, average everolimus Cmins were significantly lower by 2.9-fold in the absence vs. presence of cyclosporine: 2.9 +/- 2.8 vs. 8.3 +/- 3.7 ng/mL (p < 0.001).",Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],8.3,240930,DB00877,Sirolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],49,242441,DB00877,Sirolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],638,242442,DB00877,Sirolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],28,242443,DB00877,Sirolimus
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],318,242444,DB00877,Sirolimus
,10221478,trough levels,RAD and CsA day-14 trough levels in the staggered group were the same or lower than trough levels in animals treated with either drug alone (RAD 27+/-3/Neoral 815+/-67 ng/ml).,"Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],27,242445,DB00877,Sirolimus
,10221478,trough levels,RAD and CsA day-14 trough levels in the staggered group were the same or lower than trough levels in animals treated with either drug alone (RAD 27+/-3/Neoral 815+/-67 ng/ml).,"Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],815,242446,DB00877,Sirolimus
,19606088,area under the curve (AUC),"After 500 mg MMF, the mean MPA area under the curve (AUC) was significantly lower in sirolimus-treated patients than in those treated with tacrolimus (35.4 +/- 32.3 vs. 77.1 +/- 67.5 mg/l).",Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19606088/),[mg] / [l],35.4,242878,DB00877,Sirolimus
,19606088,area under the curve (AUC),"After 500 mg MMF, the mean MPA area under the curve (AUC) was significantly lower in sirolimus-treated patients than in those treated with tacrolimus (35.4 +/- 32.3 vs. 77.1 +/- 67.5 mg/l).",Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19606088/),[mg] / [l],77.1,242879,DB00877,Sirolimus
,30259313,Ctrough,"Among 44 evaluable patients, the geometric mean (GM) Ctrough was higher in patients with toxicity compared to patients without (17.4 versus 12.3 μg/L (p = 0.02)).",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],17.4,242948,DB00877,Sirolimus
,30259313,Ctrough,"Among 44 evaluable patients, the geometric mean (GM) Ctrough was higher in patients with toxicity compared to patients without (17.4 versus 12.3 μg/L (p = 0.02)).",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],12.3,242949,DB00877,Sirolimus
>,30259313,Ctrough,The optimal cut-off value to predict toxicity was Ctrough > 19.2 μg/L.,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],19.2,242950,DB00877,Sirolimus
,30259313,Ctrough,GM Ctrough of patients with and without progressive disease (PD) within 3 months was not significantly different (12.0 versus 15.2 μg/L (p = 0.118)).,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],12.0,242951,DB00877,Sirolimus
,30259313,Ctrough,GM Ctrough of patients with and without progressive disease (PD) within 3 months was not significantly different (12.0 versus 15.2 μg/L (p = 0.118)).,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),[μg] / [l],15.2,242952,DB00877,Sirolimus
,30259313,PFS,"Patients with <11% versus >11% decrease in SULpeak high at day 14 had a median PFS of 90 days versus 411 days, respectively (p = 0.0013) and more frequently had PD within 3 months: 70 vs 11%, respectively.",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),d,90,242953,DB00877,Sirolimus
,30259313,PFS,"Patients with <11% versus >11% decrease in SULpeak high at day 14 had a median PFS of 90 days versus 411 days, respectively (p = 0.0013) and more frequently had PD within 3 months: 70 vs 11%, respectively.",Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259313/),d,411,242954,DB00877,Sirolimus
,16418694,tmax,"The absorption of parent drug and derived materials was rapid (tmax 1.3 +/- 0.5 hours, mean +/- SD), and the elimination of sirolimus was slow (t(1/2) 60 +/- 10 hours, mean +/- SD) in whole blood.",Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418694/),h,1.3,244488,DB00877,Sirolimus
,16418694,t(1/2),"The absorption of parent drug and derived materials was rapid (tmax 1.3 +/- 0.5 hours, mean +/- SD), and the elimination of sirolimus was slow (t(1/2) 60 +/- 10 hours, mean +/- SD) in whole blood.",Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418694/),h,60,244489,DB00877,Sirolimus
,16418694,whole blood to plasma (B/P) concentration ratio,The high whole blood to plasma (B/P) concentration ratio of sirolimus (142 +/- 39) was consistent with its extensive partitioning into formed blood elements.,Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418694/),,142,244490,DB00877,Sirolimus
,16418694,B/P,The markedly lower B/P value based on radioactivity (2.7 +/- 0.4) suggested that drug-derived products partitioned into formed blood elements to a much lesser extent.,Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418694/),,2.7,244491,DB00877,Sirolimus
,17555465,trough concentrations,"Patients (n = 45) were randomized 2 : 1 to receive treatment with sirolimus (n = 30; dosed to maintain trough concentrations of 10-25 ng ml(-1) until week 8, and then 8-15 ng ml(-1) thereafter) or CsA (n = 15; administered as per centre practice) both in combination with daclizumab, oral MMF and corticosteroids.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[ng] / [ml],10-25,244711,DB00877,Sirolimus
,17555465,trough concentrations,"Patients (n = 45) were randomized 2 : 1 to receive treatment with sirolimus (n = 30; dosed to maintain trough concentrations of 10-25 ng ml(-1) until week 8, and then 8-15 ng ml(-1) thereafter) or CsA (n = 15; administered as per centre practice) both in combination with daclizumab, oral MMF and corticosteroids.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[ng] / [ml],8-15,244712,DB00877,Sirolimus
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],40.4,244713,DB00877,Sirolimus
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],68.5,244714,DB00877,Sirolimus
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],722,244715,DB00877,Sirolimus
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],485,244716,DB00877,Sirolimus
,17555465,exposure,"MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],722,244717,DB00877,Sirolimus
,17555465,exposure,"MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],485,244718,DB00877,Sirolimus
,10579146,oral availability,"The oral availability of sirolimus was increased to a modest extent (35%) and in a uniform manner when administered with a high-fat meal; the geometric mean ratio of the fed/fasting AUC values was 1.35, with a 90% confidence interval of 1.26 to 1.46.",The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579146/),%,35,244919,DB00877,Sirolimus
,10579146,terminal half-life,Food had no effect on the terminal half-life of sirolimus (mean values of 67 to 68 hours).,The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579146/),h,67 to 68,244920,DB00877,Sirolimus
,15848558,AUC0-12,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],54.1,245397,DB00877,Sirolimus
,15848558,AUC0-12,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],51.7,245398,DB00877,Sirolimus
,15848558,C0,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],3,245399,DB00877,Sirolimus
,15848558,C0,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],2.76,245400,DB00877,Sirolimus
,15848558,AUC0-12,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],32.3,245401,DB00877,Sirolimus
,15848558,C0,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],2.32,245402,DB00877,Sirolimus
,15848558,AUC0-12,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],70.9,245403,DB00877,Sirolimus
,15848558,C0,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],4.7,245404,DB00877,Sirolimus
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],256.5,247917,DB00877,Sirolimus
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],205.8,247918,DB00877,Sirolimus
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],226.1,247919,DB00877,Sirolimus
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],224.4,247920,DB00877,Sirolimus
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],25.3,247921,DB00877,Sirolimus
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],24.9,247922,DB00877,Sirolimus
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],26.7,247923,DB00877,Sirolimus
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],37.1,247924,DB00877,Sirolimus
,10594869,dose corrected C(max),"In addition, the dose corrected C(max) was lower in the solid tablet PK profiles compared with the prior PK profiles for the liquid (7.7 versus 10.2 ng/mL, p<0.02).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],7.7,247925,DB00877,Sirolimus
,10594869,dose corrected C(max),"In addition, the dose corrected C(max) was lower in the solid tablet PK profiles compared with the prior PK profiles for the liquid (7.7 versus 10.2 ng/mL, p<0.02).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],10.2,247926,DB00877,Sirolimus
,28923619,trough level,Target trough level of EVL was 3-8 ng/mL.,Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],3-8,249097,DB00877,Sirolimus
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],"309 to 1,896",249098,DB00877,Sirolimus
,28923619,area under the receiver operating characteristic curve (AUC),"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],"3,449",249099,DB00877,Sirolimus
,28923619,C0,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],5.2,249100,DB00877,Sirolimus
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],15.4,249101,DB00877,Sirolimus
,28923619,AUC,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],99.7,249102,DB00877,Sirolimus
,11719728,apparent clearance,The apparent clearance of everolimus was significantly reduced by 53% in subjects with moderate hepatic impairment compared with healthy subjects (9.1 +/- 3.1 versus 19.4 +/- 5.8 L/h).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),[l] / [h],9.1,251717,DB00877,Sirolimus
,11719728,apparent clearance,The apparent clearance of everolimus was significantly reduced by 53% in subjects with moderate hepatic impairment compared with healthy subjects (9.1 +/- 3.1 versus 19.4 +/- 5.8 L/h).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),[l] / [h],19.4,251718,DB00877,Sirolimus
,11719728,area under the blood concentration-time curve (AUC),This was manifested by a 115% higher area under the blood concentration-time curve (AUC) (245 +/- 91 versus 114 +/- 45 ng.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),ng,245,251719,DB00877,Sirolimus
,11719728,area under the blood concentration-time curve (AUC),This was manifested by a 115% higher area under the blood concentration-time curve (AUC) (245 +/- 91 versus 114 +/- 45 ng.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),ng,114,251720,DB00877,Sirolimus
,11719728,half-life,h/ml) and 84% prolonged half-life (79 +/- 42 versus 43 +/- 18 hours) in subjects with hepatic impairment.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),h,79,251721,DB00877,Sirolimus
,11719728,half-life,h/ml) and 84% prolonged half-life (79 +/- 42 versus 43 +/- 18 hours) in subjects with hepatic impairment.,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),h,43,251722,DB00877,Sirolimus
,11719728,Protein binding,Protein binding was similar in the two groups (73.8% +/- 3.6% versus 73.5% +/- 2.4%).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),%,73.8,251723,DB00877,Sirolimus
,11719728,Protein binding,Protein binding was similar in the two groups (73.8% +/- 3.6% versus 73.5% +/- 2.4%).,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719728/),%,73.5,251724,DB00877,Sirolimus
,21107682,progression-free survival,"ORR was 19.1%, with a disease control rate of 83.0% and median progression-free survival of 30.7 weeks.",Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107682/),weeks,30.7,252471,DB00877,Sirolimus
,27299325,apparent volume of distribution,"The apparent volume of distribution of the central and peripheral compartment were estimated to be 207 L with a relative standard error (RSE) of 5.0 % and 485 L (RSE 4.2 %), respectively, with an inter-compartmental clearance of 72.1 L/h (RSE 3.2 %).",A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),l,207,252744,DB00877,Sirolimus
,27299325,apparent volume of distribution,"The apparent volume of distribution of the central and peripheral compartment were estimated to be 207 L with a relative standard error (RSE) of 5.0 % and 485 L (RSE 4.2 %), respectively, with an inter-compartmental clearance of 72.1 L/h (RSE 3.2 %).",A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),l,485,252745,DB00877,Sirolimus
,27299325,inter-compartmental clearance,"The apparent volume of distribution of the central and peripheral compartment were estimated to be 207 L with a relative standard error (RSE) of 5.0 % and 485 L (RSE 4.2 %), respectively, with an inter-compartmental clearance of 72.1 L/h (RSE 3.2 %).",A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),[l] / [h],72.1,252746,DB00877,Sirolimus
,27299325,apparent intrinsic clearance,The apparent intrinsic clearance was 198 L/h (RSE 4.3 %).,A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27299325/),[l] / [h],198,252747,DB00877,Sirolimus
,15049795,weight,"Based on an inter-study analysis, weight-normalized CL/F in the current population of younger pediatric dialysis patients (5-11 yr, 544 +/- 463 mL/h/kg, n = 7) was increased by 90% (p < or = 0.05) compared with healthy adults (19-36 yr, 287 +/- 111 mL/h/kg, n = 25).","Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049795/),[ml] / [h·kg],544,254238,DB00877,Sirolimus
,15049795,weight,"Based on an inter-study analysis, weight-normalized CL/F in the current population of younger pediatric dialysis patients (5-11 yr, 544 +/- 463 mL/h/kg, n = 7) was increased by 90% (p < or = 0.05) compared with healthy adults (19-36 yr, 287 +/- 111 mL/h/kg, n = 25).","Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049795/),[ml] / [h·kg],287,254239,DB00877,Sirolimus
,17038875,time after dose,"A total of 31 patients (7 female and 24 male) originally included in a formal clinical trial, contributed 524 sirolimus blood concentrations with the time after dose ranging from 11.08 to 31.83 hours.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038875/),h,11.08 to 31.83,254362,DB00877,Sirolimus
,17038875,CL/F,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1,350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038875/),[l] / [h],7.09,254363,DB00877,Sirolimus
,17038875,apparent volume of distribution,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1,350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038875/),[l] / [h],"1,350",254364,DB00877,Sirolimus
,16995863,apparent clearance (CL/F ),The typical value for the apparent clearance (CL/F ) was 12.5 l h(-1) at the median age of 44 years.,A Bayesian approach for population pharmacokinetic modelling of sirolimus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995863/),[l] / [h],12.5,257170,DB00877,Sirolimus
,27128614,maximum concentration (Cmax ),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[ng] / [ml],14.1,258131,DB00877,Sirolimus
,27128614,area under the concentration-time curve within a dosing interval of τ (AUCτ ),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[h·ng] / [ml],199,258132,DB00877,Sirolimus
,27128614,area under the concentration-time curve within a dosing interval of τ (AUCτ ),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[l] / [h],10.1,258133,DB00877,Sirolimus
,27128614,oral clearance (CL/F),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[h·ng] / [ml],199,258134,DB00877,Sirolimus
,27128614,oral clearance (CL/F),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[l] / [h],10.1,258135,DB00877,Sirolimus
,27128614,trough concentration (Ctrough ) at steady state,"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[ng] / [ml],5.9,258136,DB00877,Sirolimus
,27128614,tmax,Median tmax (range) was 2.49 hours (1-12 hours).,Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),h,2.49,258137,DB00877,Sirolimus
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,80.7,258222,DB00877,Sirolimus
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,94,258223,DB00877,Sirolimus
,17201457,absolute bioavailability,EC-mycophenolate sodium has an absolute bioavailability of MPA of approximately 72%.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,72,258224,DB00877,Sirolimus
,17201457,lag time in absorption,EC-mycophenolate sodium exhibits a median lag time in absorption of MPA from 0.25 to 1.25 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,0.25 to 1.25,258225,DB00877,Sirolimus
,17201457,elimination half-life,The mean elimination half-life of MPA ranges from 9 to 17 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,9 to 17,258226,DB00877,Sirolimus
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],14.1 to 34.9,258227,DB00877,Sirolimus
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],11.9 to 25.4,258228,DB00877,Sirolimus
,17201457,AUC from 0 to 12 hours (AUC12),Targeting a total MPA AUC from 0 to 12 hours (AUC12) of 30-60 mg.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),mg,30-60,258229,DB00877,Sirolimus
,24935294,C0,"In this phase 3, multicenter, randomized, open-label study, patients were randomized (1:1) to 1 of the 2 groups: everolimus 1.5 mg (targeted C0 of 3-8 ng/mL) plus reduced-dose cyclosporine or mycophenolate mofetil 2 g/d plus standard-dose cyclosporine.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3-8,259795,DB00877,Sirolimus
,24935294,trough concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],4.307,259796,DB00877,Sirolimus
,24935294,peak concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],13.539,259797,DB00877,Sirolimus
,24935294,area under the concentration-time curve,"The average concentration was 7.558 ± 1.4723 ng/mL, area under the concentration-time curve was 90.70 ± 17.667 ng·h/mL, and peak-trough fluctuation was 122.6%.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[h·ng] / [ml],90.70,259798,DB00877,Sirolimus
,24935294,trough levels,"The mean everolimus trough levels were within the target ranges at all time points ranging from 3.4 to 5.5 ng/mL (everolimus 0.75 mg twice a day, safety population).",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3.4 to 5.5,259799,DB00877,Sirolimus
,34224367,tumor tissue drug concentration,"Median tumor tissue drug concentration determined by mass spectrometry was 24.3 pg/mg (range, 9.2-169.2).",Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34224367/),[pg] / [mg],24.3,260403,DB00877,Sirolimus
,17532692,half-life,The mean half-life ranged between 26.0 and 40.2h over the studied doses and was not significantly different over the 300-900mug dose range.,"Pharmacokinetics and Safety of ABT-578, a Sirolimus (Rapamycin) Analogue, after Single Intravenous Bolus Injection in Healthy Male Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532692/),h,26.0 and 40.2,260838,DB00877,Sirolimus
,17532692,clearance,The mean clearance values ranged from 2.90 to 3.55 L/h.,"Pharmacokinetics and Safety of ABT-578, a Sirolimus (Rapamycin) Analogue, after Single Intravenous Bolus Injection in Healthy Male Volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532692/),[l] / [h],2.90 to 3.55,260839,DB00877,Sirolimus
,21168621,C(0),We enrolled 10 de novo kidney transplant recipients to receive CsA (target C(0) 250-350 ng/mL) and prednisolone as initial therapy.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],250-350,260925,DB00877,Sirolimus
,21168621,target,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260926,DB00877,Sirolimus
,21168621,trough level,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260927,DB00877,Sirolimus
,21168621,trough level,CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],50-100,260928,DB00877,Sirolimus
<,21168621,C(max),CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],600,260929,DB00877,Sirolimus
,21168621,initial trough everolimus,The mean initial trough everolimus was 5.2 ± 1.5 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],5.2,260930,DB00877,Sirolimus
,22872575,area under the concentration curve (AUC),"The target sirolimus area under the concentration curve (AUC) of 3,810 ng-h/mL was achieved at sirolimus doses of 90, 16, and 25 mg in the sirolimus alone, sirolimus plus ketoconazole, and sirolimus plus grapefruit juice studies, respectively.",Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22872575/),[ng-h] / [ml],"3,810",262847,DB00877,Sirolimus
,22664810,T(max),"Across all dose levels, individual T(max) values ranged from 1.00 hour and 12.00 hours; individual C(max) ranged from 0.73 ng/mL and 4.13 ng/mL.",Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664810/),h,1.00,265016,DB00877,Sirolimus
,22664810,T(max),"Across all dose levels, individual T(max) values ranged from 1.00 hour and 12.00 hours; individual C(max) ranged from 0.73 ng/mL and 4.13 ng/mL.",Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664810/),h,12.00,265017,DB00877,Sirolimus
,22664810,C(max),"Across all dose levels, individual T(max) values ranged from 1.00 hour and 12.00 hours; individual C(max) ranged from 0.73 ng/mL and 4.13 ng/mL.",Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664810/),[ng] / [ml],0.73,265018,DB00877,Sirolimus
,22664810,C(max),"Across all dose levels, individual T(max) values ranged from 1.00 hour and 12.00 hours; individual C(max) ranged from 0.73 ng/mL and 4.13 ng/mL.",Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664810/),[ng] / [ml],4.13,265019,DB00877,Sirolimus
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],15,265254,DB00877,Sirolimus
,15831774,maximum concentration,"During ketoconazole coadministration, everolimus maximum concentration increased 3.9-fold (90% confidence interval, 3.4-4.6) from 15 +/- 4 ng/mL to 59 +/- 13 ng/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[ng] / [ml],59,265255,DB00877,Sirolimus
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],90,265256,DB00877,Sirolimus
,15831774,area under the curve,"Everolimus area under the curve increased 15.0-fold (90% confidence interval, 13.6-16.6) from 90 +/- 23 ng*h/mL to 1324 +/- 232 ng*h/mL.",Blood concentrations of everolimus are markedly increased by ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),[h·ng] / [ml],1324,265257,DB00877,Sirolimus
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,30,265258,DB00877,Sirolimus
,15831774,half-life,Everolimus half-life was prolonged by 1.9-fold from 30 +/- 4 hours to 56 +/- 5 hours.,Blood concentrations of everolimus are markedly increased by ketoconazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831774/),h,56,265259,DB00877,Sirolimus
,16467100,MTD,"The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs.",Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467100/),mg,500,265969,DB00877,Sirolimus
,16467100,MTD,"The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs.",Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467100/),mg,1,265970,DB00877,Sirolimus
,22241793,peak,Whole blood sirolimus levels rose to a mean peak of 4.8 ng/mL at 6 h and fell to <1 ng/mL at 1 week (n = 5).,Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22241793/),[ng] / [ml],4.8,267714,DB00877,Sirolimus
,22241793,thrombosis rate,"Twelve and 24-month primary unassisted patencies were 76 and 38%, respectively, and the thrombosis rate was 0.37/patient-year.",Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22241793/),1/[patient-year],0.37,267715,DB00877,Sirolimus
,23666574,clearance,"Mean sirolimus clearance was 11.8 L/h (SD 4.6, range 2.2-24.1), and the mean dose to obtain a target trough concentration of 10-15 ng/mL was 2.0 mg/m administered twice daily (SD 0.72, range 0.77-3.85).",Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666574/),[l] / [h],11.8,270397,DB00877,Sirolimus
,23666574,trough concentration,"Mean sirolimus clearance was 11.8 L/h (SD 4.6, range 2.2-24.1), and the mean dose to obtain a target trough concentration of 10-15 ng/mL was 2.0 mg/m administered twice daily (SD 0.72, range 0.77-3.85).",Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666574/),[ng] / [ml],10-15,270398,DB00877,Sirolimus
,23666574,trough concentrations,A mean dose of 2.0 mg/m twice a day was required for attainment of target trough concentrations of 10-15 ng/mL in children greater than 3 years of age who have NF1.,Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666574/),[ng] / [ml],10-15,270399,DB00877,Sirolimus
,11034258,whole blood terminal disposition half-life (t1/2),"Mean (+/- SD) whole blood terminal disposition half-life (t1/2), apparent oral dose clearance (Cl/F), and volume of distribution (Vss/F) were 82 +/- 12 hours, 278 +/- 117 mL/h x kg and 23 +/- 10 L/kg, respectively.",Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034258/),h,82,272492,DB00877,Sirolimus
,11034258,apparent oral dose clearance (Cl/F),"Mean (+/- SD) whole blood terminal disposition half-life (t1/2), apparent oral dose clearance (Cl/F), and volume of distribution (Vss/F) were 82 +/- 12 hours, 278 +/- 117 mL/h x kg and 23 +/- 10 L/kg, respectively.",Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034258/),[ml] / [h·kg],278,272493,DB00877,Sirolimus
,11034258,volume of distribution (Vss/F),"Mean (+/- SD) whole blood terminal disposition half-life (t1/2), apparent oral dose clearance (Cl/F), and volume of distribution (Vss/F) were 82 +/- 12 hours, 278 +/- 117 mL/h x kg and 23 +/- 10 L/kg, respectively.",Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034258/),[l] / [kg],23,272494,DB00877,Sirolimus
,11034258,whole blood-to-plasma ratio,"Distribution of sirolimus into formed blood elements was extensive, with a mean whole blood-to-plasma ratio of 36.",Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034258/),,36,272495,DB00877,Sirolimus
,27117038,absorption rate constant (Ka),"The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively.",Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27117038/),1/[h],0.24,273202,DB00877,Sirolimus
,27117038,clearance (CL/F),"The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively.",Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27117038/),[l] / [h],8.81,273203,DB00877,Sirolimus
,27117038,central volume of distribution (V2/F),"The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively.",Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27117038/),l,676,273204,DB00877,Sirolimus
,18094423,tissue to whole blood ratio,The average tissue to whole blood ratio for temsirolimus was 1.43 and 0.84 for sirolimus.,Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094423/),,1.43,273320,DB00877,Sirolimus
,18094423,tissue to whole blood ratio,The average tissue to whole blood ratio for temsirolimus was 1.43 and 0.84 for sirolimus.,Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094423/),,0.84,273321,DB00877,Sirolimus
,23134470,MTDs,Daily and weekly MTDs were 7.5 mg and 70 mg respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),mg,7.5,273848,DB00877,Sirolimus
,23134470,MTDs,Daily and weekly MTDs were 7.5 mg and 70 mg respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),mg,70,273849,DB00877,Sirolimus
,23134470,Disease control rates,Disease control rates in the daily and weekly cohorts were 71.4% and 44.4% respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),%,71.4,273850,DB00877,Sirolimus
,23134470,Disease control rates,Disease control rates in the daily and weekly cohorts were 71.4% and 44.4% respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),%,44.4,273851,DB00877,Sirolimus
<,29574974,trough levels,"In transplant patients, the approved dose of 0.75-1 mg twice daily (BID) results in subtherapeutic trough levels (<6 μg l-1 ) and that a higher starting dose of 2.25-3 mg BID is required.",A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29574974/),[μg] / [l],6,274094,DB00877,Sirolimus
